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Despite all the interventions deployed to control tuberculosis (TB), the disease still continues to be 
the principal cause of death from a single infectious agent in resource constrained settings. An 
estimated 60% of suspected TB patients do not have access to TB diagnostic tests. With the 
limitations of the current diagnostic tests and the importance of early diagnosis and initiation of 
treatment, biomarker diagnosis of TB would be an optimal option. For biomarkers are indicators of 
immune activity and state. Therefore, host or pathogen biomarker of TB disease would be ideal. 
Hence, the aim of this project was to profile a broad array of host markers for development of optimal 
signatures for detection of pulmonary tuberculosis from other respiratory disorders using ex vivo 
sputum samples 
Methods
We recruited patients who were seeking medical attention at the MRCG at LSHTM outpatients 
department and Tuberculosis clinic with symptoms suggestive of TB, prior to clinical or 
microbiological diagnosis. All age groups were recruited. Sputa were collected at baseline from all 
participants and at 1 and 2 months from the confirmed TB cases. The sputa were digested with 
Sputolysin and the supernatant analysed using Luminex arrays while RNA extracted from the pellet 
were analysed with RT-qPCR. Statistical analyses and graphs were generated using R programming 
Language and GraphPad Prism, with a q value ≤ 0.05 considered significant.  A receiver operating 
curve (ROC) was used to assess the diagnostic performance of individual and combination markers. 
Results 
Confirmed TB (428) and ORD (313) patients were analysed, 70 markers were assessed for 
diagnostic potential and treatment response. Of these, 37 were significantly different between TB 
and ORD. The best single marker was MMP-2 with an AUC of 0.73. An eight-marker signature (IFN-
ү, IL-1β, IL-8, IL-10, IL-12p70, MIP-1β, RANTES and VEGF) was able to diagnose smear and culture 
positive TB from ORD with an AUC of 0.77, sensitivity of 78% and specificity of 70%, while a three-
marker signature (IL-1β, IL-7 and VEGF) classified smear negative but culture positive TB from ORD 
with an AUC of 0.74, sensitivity of 86% and specificity of 60%. Among children who had TB, a four-
marker signature (FGF, IL-4, MIP-1a and RANTES) differentiated those with TB from ORD, with an 
AUC of 0.87, sensitivity of 82% and specificity of 87% and a five-marker signature consisting of 
BAFF, C3L1, IL-22, MMP-3 and sTNFR1 was able to discriminate TB and HIV co-infected from ORD 
with an AUC of 0.90, sensitivity of 88% and specificity of 85%. We also found a four-marker signature 
consisting of EGF, IL-15, MIP-1β and TNF-β that could predict slow versus fast treatment responders 




We have discovered novel sputum host biomarkers and biosignatures for screening of tuberculosis 
and treatment response. The data is promising for potential translation into a user friendly device as 
a rapid screening test for pulmonary TB. However, this markers and signatures require further 





Ten spyte van al die ingrypings wat toegepas word om tuberkulose (TB) te beheer, bly die siekte 
steeds die grootste oorsaak van die dood van 'n enkele aansteeklike middel in beperkte hulpbronne. 
Na raming het 60% van die vermoedelike TB-pasiënte nie toegang tot diagnostiese toetse vir TB 
nie. Met die beperkinge van die huidige diagnostiese toetse en die belangrikheid van vroeë diagnose 
en inisiëring van behandeling, sou die biomerk-diagnose van TB 'n optimale opsie wees. Vir 
biomerkers is dit 'n aanduiding van immuunaktiwiteit en toestand. Daarom is gasheer- of 
patogeenbiomerker van TB-siekte ideaal. Die doel van hierdie projek was dus om 'n wye 
verskeidenheid gasheermerkers te profiel vir optimale handtekeninge vir die opsporing van 
pulmonale tuberkulose van ander respiratoriese afwykings met behulp van ex vivo sputum monsters. 
Metodes 
Ons het pasiënte gewerf wat mediese behandeling by die MRCG by LSHTM-buitepasiënte-afdeling 
en tuberkulosekliniek opgedoen het met simptome wat dui op TB, voor die kliniese of mikrobiologiese 
diagnose. Alle ouderdomsgroepe is gewerf. Sputa is vanaf die beginlyn by alle deelnemers versamel 
en op 1 en 2 maande van die bevestigde TB-gevalle. Die sputa is met Sputolysin verteer en die 
supernatant is met behulp van Luminex-skikkings geanaliseer terwyl RNA wat uit die korrel onttrek 
is, met RT-qPCR geanaliseer is. Statistiese ontledings en grafieke is gegenereer met behulp van R-
programmeringstaal en GraphPad-prisma, met 'n q-waarde ≤ 0,05 wat as beduidend beskou is. 'N 
Ontvangerbedryfskurwe (ROC) is gebruik om die diagnostiese prestasie van individuele en 
kombinasiemerkers te beoordeel. 
Resultate 
Bevestigde TB (428) en ORD (313) pasiënte is geanaliseer, 70 merkers is beoordeel vir diagnostiese 
potensiaal en reaksie op die behandeling. Hiervan was 37 aansienlik verskillend tussen TB en ORD. 
Die beste enkele merker was MMP-2 met 'n AUC van 0,73. 'N Handtekening met 'n agt merker (IFN-
ү, IL-1β, IL-8, IL-10, IL-12p70, MIP-1β, RANTES en VEGF) was in staat om die smeer- en kultuur-
positiewe TB van ORD te diagnoseer met 'n AUC van 0.77 , sensitiwiteit van 78% en spesifisiteit 
van 70%, terwyl 'n drie-merkteken (IL-1β, IL-7 en VEGF) die negatiewe maar kultuurpositiewe TB 
van ORD met 'n AUC van 0.74, 'n sensitiwiteit van 86% en die spesifisiteit van 60%. Onder kinders 
wat TB gehad het, het 'n vierteken-handtekening (FGF, IL-4, MIP-1a en RANTES) diegene met TB 
van ORD onderskei, met 'n AUC van 0,87, 'n sensitiwiteit van 82% en die spesifisiteit van 87% en 'n 
vyf- merkerhandtekening bestaande uit BAFF, C3L1, IL-22, MMP-3 en sTNFR1 was in staat om TB 
en MIV wat mede-besmet was van ORD te onderskei met 'n AUC van 0,90, 'n sensitiwiteit van 88% 






15, MIP-1β en TNF-β wat reageer op 'n trae versus vinnige behandeling by die basislyn met 'n AUC 
van 0,74, 'n sensitiwiteit van 75% en die spesifisiteit van 80%. 
 
Afsluiting 
Ons het nuwe sputum gasheer-biomerkers en biohandtekeninge ontdek vir die keuring van 
tuberkulose en reaksie op die behandeling. Die data is belowend vir moontlike vertaling in 'n 
gebruikersvriendelike toestel as 'n vinnige siftingstoets vir long-TB. Hierdie merkers en 
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 Overview of Tuberculosis  
Tuberculosis (TB) disease continuous to be a menace to humans for centuries. More people  actually 
died of the disease compared other infectious diseases around the world, with 1.6 million deaths in 
2017 alone [1]. The disease is caused by Mycobacterium tuberculosis (Mtb) complex (MTBC) [2]. 
M. tuberculosis sensu stricto is the predominant sub-species while other species like Beijing, M. 
canettii and M. africanum can also cause TB in different regions [2]. The M. africanum strain is 
localised mainly in the West African sub region [2]. Robert Koch discovered the bacterium [3], [4]. 
However, emergence of Mtb is not well understood. Studies have postulated that the pathogen came 
from the soil, and the rearing of domestic animals facilitated its contact with the human population[5]. 
With advance in TB  research, newer studies have shown Mtb not to be a descendant of, but a close 
relative to, Mycobacterium bovis (M. bovis), that  cause similar disease in livestock, thus suggesting 
the two pathogens may have simultaneously evolved together [6], [7].  
The Mtb pathogen requires oxygen for its survival, hence, its’ preferred niche is the lungs where 
there is sufficient oxygen. In addition, Mtb is a nonmotile and rod-shape bacterium duplicating every 
18-24 hours [7], [8]. It also has a distinct cell wall, characterised by its appearance under a Gram’s 
stain. Even though this bacterium has been studied extensively, no consensus has been reached 
about its classification, due its complex cell wall [2], [9], which consists of various lipids, that provides 
cushion against antibiotics and dehydration [2], [10]. Moreover, the complex composition of the cell 
wall of the bacterium is also important for its pathogenesis and virulence [2].  
 Epidemiology of Tuberculosis  
Mtb is transmitted through the intake of aerosolised particles containing the pathogen (bacilli) from 
an infectious individual. The disease mostly affects the lung (termed pulmonary TB (pTB)) but may 
attack other body parts of the infected individuals for instance:  the spine, bones or kidneys spreading 
via circulatory systems (termed extra pulmonary TB (EpTB)) [4]. The World Health Organisation 
(WHO) annual report of 2018, projected a 1.7 billion people to be latently infected with Mtb [1], [11], 
thus constituting a large reservoir for potential TB reactivation. And as of 2017, 10 million people 








infected individuals [12].These figures are unacceptably high if early diagnosis and treatment were 
possible, since majority of active cases often have drug-sensitive TB. 
Despite all the interventions deployed to control TB, the disease still continues to be the biggest killer 
among infectious agents, especially in low and middle income countries such as The Gambia [11], 
[13]. Overcrowding and poor living standards are major contributors to continued TB transmission. 
Although nearly 2 billion people around the globe are estimated to be infected with Mtb, less than 5 
-10% will go on to develop the disease in their lifetime, while most infected people would remain 
latently infected for life (1). The quick progression from latent infection to active TB is associated with 
the duration or the degree of exposure, the quantity of bacilli breathe in, the strain of infection and 
competence of the immune system of those  infected to contain the infection. People  with  weakened 
immune systems such as those with diabetes, malnutrition or HIV, are at greater risk of progressing 
to disease [11]. Therefore, the availability of an effective vaccine is essential to curb TB transmission 
and reduce morbidity and mortality. However, Bacillus Calmette–Guérin (BCG) is the only approved 
vaccine against TB, developed over a century ago and mostly effective against military and 
Meningitis TB among children. Its effect is known to wane with age. It provides no protection against 
pulmonary TB or reinfection, therefore is a new vaccine is needed. Due to these limitations of the 
BCG vaccine, an intensive search for a new vaccine against TB is ongoing. A vaccine which can 
protect against all forms of TB regardless of age, ethnicity or HIV status. The aim is to get a vaccine 
that can enhance or substitute BCG. Currently few potential vaccine candidates are on clinical trial 
such as: VPM1002 – this vaccine has under gone several phases of clinical trials both in new-borns 
and adults. Previous studies found this vaccine to be safe and immunogenic. Thus, a phase IIb trial 
of VPM1002 is presently on going in South Africa, looking at infants with and without HIV exposure 
[14]. A similar study of the same vaccine is also taking place in India assessing recurrent TB among 
cure TB patients [14]. Another vaccine under investigation is MTBVAC also at Phase 2 clinical trials 
in both new-borns and adults in South Africa. It was considered safe and tolerable when compared 
to BCG [15]. Other vaccines under investigation include  DAR-901, M. vaccae, MIP, Ad5Ag85A, 
ChAdOx185A/MVA85A, TB/FLU-04Land M72/AS01E [16]. 
The failure to properly control TB have been attributed to many things such as the high operational 
cost, suboptimal performance of current diagnosis and the moderate performance of the current 
vaccine. These in conjunction with the emerging multi and extremely drug resistant forms of TB piled 
pressure on numerous TB control mechanisms. Nonetheless, the effort to stop TB was not in vain, 
for there was a significant global decline in TB related deaths by 22% from 2000 – 2016 with 53 
million lives saved [17]. However, this global drop was most notable in Eastern Mediterranean and 








A major challenge with controlling TB is having access to an accurate, simple, cheap, and rapid TB 
diagnostic test. Approximately 60% of TB patients visit basic healthcare centres to seek medication, 
but most of these health centres have very little diagnostic infrastructure [18]. Early diagnosis is 
crucial in controlling TB, since each patient can transmit the bacteria to a least 10 - 15 people in a 
single year  prior to diagnosis [19], [20]. Therefore, early diagnosis and treatment will help to block 
the transmission chain and ultimately help to bring TB under control. 
 
 
Figure 1.1  Estimated TB Incidence rates 2018 [12] 
 
 Basic immunology of tuberculosis  
The body defence against any invading microbe or pathogen is the immune system. It is a highly 
controlled process that is able to recognise and neutralise or eliminate any invading pathogen. The 
system constitutes a network of cells and molecules classified into two subclasses: the inborn, 
sometime refers to as the innate and the acquired or adaptive immune systems. The two arms 









 Innate immunity 
Innate immunity is an inborn immunity and is always the first point of call against invading pathogens. 
It has the ability to block, recognise and respond quickly to various pathogens attacking the body 
[22], [24], [25]. It constitutes the physical (skin, mucosal lining, tears, saliva, urine and cilia), chemical 
(fatty and lactic acids, lysozymes, chemokine and cytokines) and cellular components [22], [25]. The 
cellular component is only called to action when the intruding pathogen is able to penetrate physical 
barrier. Cells associated with the innate immune response are mostly natural killer (NK) cells, 
dendritic cells (DC), monocytes, macrophages, mast cells, neutrophils, eosinophil and basophils in 
conjunction with the complement pathway [21], [22].  Also recruited to the affected area  are  mucosal 
associated invariant T (MAIT) cells, gamma delta T cell  and invariant NKT cells [26]. These innate 
cells are armed with pathogen recognition receptors (PRRs) which recognise similar structures 
present on the invading pathogen - pathogen-associated molecular patterns (PAMPs) [21], [24] or 
detect molecules that are released when a cell is lysed or tissue is damaged - damage-associated 
molecular patterns (DAMPs) [27]. In addition, it is also the function of innate immunity to distinguish 
what is foreign (non-self) from what is part of the body (self). Innate also instructs and directs the 
adaptive immune responses when overwhelm with pathogen infiltration [28]. 
When Mtb is inhaled, it passes via the respiratory track to the lung then picked up by its favoured 
host cell, the alveolar macrophages(AM) [29]. Aligning the surface of the respiratory track are mucus 
and cilia, under which lie airway epithelial cells (AEC). The AEC are considered to be the initial cells 
to encounter the Mtb [29]–[33]. Previous studies have also shown that AEC could be infected by Mtb 
on their path to lungs [33], [34] thus, inducing MAIT cells cytokine production [33] setting the stage 
for Mtb control. The stimulation of the MAIT induced IFN-ү production, providing resistance to Mtb 
prior to the arrival of the cell mediated immunity [35]. Other set of cells also present in the lung, 
intestine and skin are innate lymphoid cells (ILC3) [36]. The ILC3 cells are characteristic by the 
release of IL-22, IL-17A, GM-CSF, and/or IFN-γ in response to IL-23 and IL-1β [36], [37]. ILCs are 
of three types – ILC1 known to provide protection against virus, ILC2 which resembles CD4+ Th2 
cells protect against helminth infections and allergies while ILC3 provide immunity, promote healing 
and maintaining immune balance post infection [36], [37]. A previous study have shown elevated 
ILC3 cells among active TB, but decreased in the course of treatment period while in experimental 
mouse model, similar rise in ILC3 and macrophage were also seen, however, in mice that lacked 
ILC3, a few alveolar macrophage were noticed,  as a result an inefficient control of Mtb infection was 
observed [38]. A similar observation was seen with IL-17, IL-22 and IL-23, ILC3 associated 
cytokines.  Thus suggesting ILC3 resistance against Mtb infection [38]. An important step for the 








the immune cells detect the PAMPs on the Mtb via Toll Like Receptors (TLRs) [30], [34], PRRs such 
as nucleotide oligomerization domain 2 (NOD2) [39], c-type lectin receptors, mannose receptor, 
mannose-binding lectins (MBLs) and DC-specific intercellular adhesion molecule-grabbing non-
integrin (DC-SIGN) [19], [30], [31], [39], [40]. While complement, an essential component of innate 
immunity, enhances bacterial uptake by opsonisation through the complement factor 3 (C3) [40]. 
The absence of C3 reduces phagocytic ability of immune cells by an estimated 70% [40]. AECs or 
AMs release antimicrobial substances (lysozymes, lactoferrin, defensins, ROS, NO, 
chemokine/cytokines) [34], [41] to inhibit or kill the invading Mtb.  
While the immune system is trying to get rid of the Mtb, the pathogen has developed numerous ways 
of escaping the immune response such as the masking from PRRs by Mtb cell surface-associated 
phthiocerol dimycocerosate (PDIM) lipids or the recruitment of impair macrophages that are limited 
in producing reactive nitrogen and oxygen species thus favouring pathogen survival [42]. In addition 
the presence of mannose-capped lipoarabinomannan (ManLAM) has been implicated in blocking 
calcium (Ca2+) reaching the cytosol of macrophage, inhibiting phagosome maturation, promoting 
disease pathogenesis [26], [43], [44]. Furthermore, Mtb in a bid to survive obstruct cell apoptosis, a 
pro Mtb elimination process in favour of necrosis, a strategy to promote its spread and thus delay 
the adaptive immune response’s arrival has also been suggested [44], [45]. In fact the increase influx 
of cells to the site of injury or inflammation has been attributed to promoting bacteria spread due to 
the infection of  some the arriving cells by Mtb [44], [45] 
 Adaptive immunity 
As the innate immune response becomes overwhelmed by pathogen expansion, the adaptive 
immune response kicks in. This is observed by arrival of specific immune responses tailored towards 
the disease-causing agent [28]. And the subsequent presence of memory cells to prevent reinfection 
by the same pathogen [25], however in TB no memory cells are shown to be associated with Mtb 
protection [46]. The adaptive immune responses constitutes two arms, a) humoral (B cells) and b) 
cell mediated (T cells). The humoral response is facilitated by B cells, which release antibodies into 
the blood stream to neutralise the invading pathogen. These activated B cells also aid T cell 
stimulation through antigen presentation hence amplifying the immune response.  In turn, triggering  
T cells response with complex immune reactions, recruiting various cells to contain the pathogen 
[28].  Among the tasks of the T cells is to aid B cells and phagocytic cells activation, hence the name 
helper T cells. T cells are recognised by cluster of difference (CD3), which consist of two main 
populations: CD8 cell sometimes refer to as cytotoxic lymphocytes (CTL) and CD4 known as helper 








APC, thus killing the infected cells [28]. While the CD4 T cell when activated stimulate the arrival 
other immune cells to site of injury. CD4 cells can differentiate into many subsets define by the 
cytokine they produce: Th1, Th2, Th9, Th17, Th22, Treg (regulatory T cells)[47], [48], and Tfh 
(follicular helper T cells)[49], as shown in Figure 1.2 below. CD4 T cells bind to MHC class II of the 
APC, activating other immune cells like macrophages or promoting B cell activation.  
 
Figure 1.2  CD4 T cell differentiation upon activation leading to different subsets of cells and their 
functions, characterised by the cytokines they produced [48] 
The best described subsets of CD4+ cells are Th 1, Th2, Th17 and T regulatory (Treg) cells. Th1 
cells are pro-inflammatory, characterised by secretion of IFN-ү, IL-12, TNF-α and IL-2 [47], [48]. IL-
12 induces STAT4 in the presence of T-bet to amplify IFN-ү release, thus aiding immune cell 
recruitment to fight invading pathogens. Uncontrolled Th1 responses can be detrimental, as seen in 
some autoimmune diseases [49]. Th2 cells are anti-inflammatory and identified by the release of IL-
4 in the presence of GATA-3 transcription factor. IL-4R/STAT6 enhance the production of GATA-3, 
thus enhancing the differentiation of Th2 cells [49]. Other cytokines attributed to Th2 response 
includes IL-5, IL-9, IL-10, and IL-13 [47], [48]. In contrast to Th1 cells, Th2 cells aid B-cells in the 
production of antibodies against extracellular parasites such as Helminths, but excess response of 
Th2 cells could lead to allergic reactions and airway hypersensitivity [49]. Th2 cells can be 
recognised by the presence of CCR4, which is responsible for cell recruitment. Th17 cells are 
associated with the release of IL-17, IL-21, IL-22 and IL-26 [47], [50]. IL-6 and TGF-β enhanced 








Th17 cells in mice, however, increased differentiation of these cell in human required the addition of 
IL-1β [51], [52]. The task of TGF-β in human Th17 development is still not well understood; some 
studies found TGF-β in humans to impede Th17 development, while in cord blood it was found to 
aid Th17 development [51]. However, Th17 responses are mostly associated with inflammation and 
tissue destruction, although they are also involved in the fight against pathogens such as bacteria 
and fungi or other eukaryotic pathogens [47]. Finally, Treg  are cells that keep in check the balance 
between the Th1 and Th2 responses and maintain self-tolerance [53], [54]. They can help to prevent 
allergy, autoimmunity, inflammation and have been shown to  promote regeneration of hair follicles 
[55]. They are characterised by the presence of IL-2R (CD25) and Forkhead box P3 (FOXP3) gene 
with the release of abundant IL-10 and TGF-β [47], [54]. TGF-β enhances CD4+ differentiation to 
Tregs. It is noted that upregulation of Tregs might be good for treatment of autoimmune diseases 
and allergies while for tumour clearance, Treg downregulation is required [55]. Excessive Tregs have 
been implicated in reduced anti-microbial immunity [54]. 
Aside, the conventional T cells, other T cells for instance Gamma delta (γδ)T cells, Mucosal-
associated invariant T cells (MAIT) cells and invariant natural killer T (iNKT) have been associated 
with anti-Mtb immunity [50] by connecting the innate and acquired immune systems [56]. γδ T cells 
are a subgroup of T cells that express gamma (γ) delta (δ) on their receptor contrary to alpha-beta 
(αβ) phenotype found on conventional/classical T cells [56]. These cells constitute a tiny population 
in the blood, about 1-5% of the T cells [50]. They are mostly found in the epithelial and mucosal 
tissues [56]. They do not require MHC for antigen recognition, but instead utilise CD1d-dependent 
proteins for antigen presentation. Sensitised γδ T cells release IFN-ү, IL-17 and TNF-α [50], [57] 
which are known to protect against Mtb infection and facilitate granuloma formation. iNKT and MAIT 
cells express TCRα chain [58] with iNKT cells accounting for about 0.01-1% [58] and MAIT cells 
about 5% [50] of lymphocytes in the blood. They both mature in the thymus needing no priming to 
function [59]. iNKT and MAIT cells recognised antigens via the MHC class I-like molecules CD1d 
[60] and MHC class I-related (MR1) [50], [59] respectively. iNKT cells promote DC maturation[60], 
[61] thus prompting pathogen destruction whereas MAIT cells are cytolytic and produce TNF-α and 
IFN-γ against an infection.  Since the onset of adaptive immunity is slow, it was hypothesised that 
MAIT and iNKT cells may be the primary producers of IFN-ү required to inhibit initial pathogen 










 The initiation of adaptive immune response  
In human Mtb infection, the arrival of the adaptive immune response can take about 5-6 weeks 
whereas in mice, it takes 10 -12 days post infection for Mtb specific CD4+ cell to emerge at the area 
of injury or inflammation [62]. The delay in priming of the Mtb specific CD4+ cells is not well 
understood, but it has been suggested that the increase  in number of Mtb bacteria in the lymph 
node may be due to the late arrival of Mtb specific CD4+ or  the lack of APC complexes to prime Mtb 
specific CD4+ cells [62], thus giving rise to the rapid increase in bacteria number and subsequently 
impeding the immune system’s ability to completely eliminate the bacteria. Another hypothesis in 
regards to the failure to clear or kill the pathogen could be due the suppression of the 
proinflammatory response by the Treg or down regulation of bacterial antigen gene expression or 
resistance to the macrophage-activating effects of interferon‑γ (IFNγ) [44]. Furthermore, in a bid to 
survive another strategy Mtb uses is necrosis, a premature cell death which is detrimental to the host 
as opposed to apoptosis required for proper activation of adaptive immune system [63] or  the 
recruitment of  impaired phagocytic cells which cannot controlled Mtb propagation [42].  
 Host - Mtb interaction  
Macrophage - Mtb interaction induces multiple immune activations and cell recruitment, resulting in 
the formation of granulomas to limit bacteria propagation. Dendritic cells (DC), macrophages and 
neutrophils collectively known as phagocytes, are the major cells to appear at the place of injury. 
They pick up and kill the invading pathogen, activating more DC, which then carry the pathogen 
antigens to the nearest lymph node, for presentation to T cells [19], [45], [64]. The interactions 
amongst the DC and T cell are very important in initiating the appropriate innate-adaptive immune 
interaction. When the T cells are activated, they release interleukin-2 (IL-2) [65], IFN-ү, TNF-α, and 
IL-17 [19], [50], [66], [67]. IL-2 promotes more T Cell proliferation [65], [68], while IFN-ү and TNF-α 
enhance phagocyte recruitment via the secretion of IL-1, IL-6, IL-12 and IL-23 from activated DC 
[66]. The increased production of IL-12, IL-18 and IFN-α produces a pro-inflammatory Th1 response 
with IFN-ү as the major facilitator [65], [68]. Whereas secreted IL-23 by DC on the other enhance 
Th17 or γδ T cells IL-17 release. IL-17 an inflammatory cytokine, in turn recruits neutrophil, which 
further promote granuloma formation thus enhancing Mtb resistance [67]. The release of IL-17 by γδ 
T cells has been suggested to protect against early Mtb infection [67], [69]. However, a continuous 
secretion of IL-17 has also been associated with causing  tissue damage, due to an influx of 
neutrophil and inflammatory proteins, for example TNF-α, IL-6 and MIP-2 [70].  In experimental 
mouse model, a lack of IL-17 was observed to impair granuloma form [67], whereas in humans 








counterpart  the LTBI, proposing the inadequate IL-17 could lead to TB disease [69]. Conversely, 
type I IFN known to induce CD8+ cells to clear viral infections, is implicated in causing disseminated 
bacterial diseases [71]. In murine experimental models, an inhibition of type I IFN was seen to 
correspond with low bacterial load [72], whereas in human studies, a high levels of Type I IFN genes 
were observed in TB disease compared to their latently infected counterparts [71]–[73]. Similar 
studies also observed type I IFN to be highly expressed among TB patients’ close contacts who later 
became active cases, suggesting the expression of type I IFN predisposes an individual to Mtb 
disease [71], [73]. Although IFN-ү is central in Mtb control, the negative feedback from type I IFN 
increases an individual risk of catching TB [74].   
TNF-α is released by numerous cells to support granuloma formation and maintenance [66]. The 
importance of TNF-α in containing Mtb was observed when LTBI individuals who underwent anti–
TNF-α therapy for autoimmune diseases progressed to active TB disease [75]. Hence the 
development of the granuloma is pivotal in the control of Mtb [19], [76]. It consists of Mtb with necrotic 
cells surrounded by lymphocytes and fibroblasts, thus, preventing bacterial dissemination in the host 
[19], [41]. TNF-α is down-regulated by Th2 cytokines (IL-10 and TGF-b) [65], thus increasing the 
chance of continuing active TB disease. The granuloma can be present in an individual for a life 
time, however, when the host immune system is weakened, dormant pathogens can reactivate [77], 
causing the granuloma to burst, spilling its contents into the blood stream resulting in an increase in 
bacterial load. This is shown best in HIV+ individuals, with decrease in CD4+ T cells resulting in lack 








 Spectrum of Mycobacterium tuberculosis infection 
Exposure to Mtb has generally been oversimplified into two outcomes – latently infected and active 
disease. As mentioned earlier, it has been postulated that about 5-10% of infected persons with Mtb 
proceed to disease in their lifetime [19], while the remainder are able to control the infection. This 
concept of control or not defines latent and active infections as static states. Of recent, researchers 
have understood that there are various stages of LTBI; there are those who do not progress to active 
TB (non-progressors) and others who gradually progress to active TB (subclinical), even though both 
do not manifest signs TB.  Hence the spectrum for LTBI is considered as a continuous dynamic 
balance between the host and Mtb pathogen. Thus, the focused has been to develop a highly 
sensitivity test that can detect individual who are most like to have disease. At the moment, the only 
available tests for Mtb infection diagnosis are tuberculin skin test (TST) and interferon gamma (IFN-
γ) release assay (IGRA) [79]. The two tests measure T cell responses toward Mtb antigens. A 
positive test from either is an indication of infection, whereas a negative test does not necessarily 
mean no infection. A negative result could be interpreted in many ways such as clearance of infection 
by the innate immune response without engaging the adaptive immune response [79], or the 
activated cells homing to the place of injury without immune memory [80]. Or it could reflect cell 
exhaustion from persistent antigenic stimulation [81]. Importantly, neither test can distinguish latent 
infection from active disease.   
 Distinguishing TB from Other respiratory disorders (ORDs) 
Respiratory disorders are diseases affecting air passages causing structural damage and narrowing 
of the airways, thus limiting gas exchange for the affected individual.  They are a huge public health 
problem accounting for about 4.6 million deaths annually [32], with many of deaths occurring in 
developing countries. They can be classified into four main categories: obstructive, restrictive, 
infectious and vascular conditions and range from mild to severe forms affecting both the lower and 
upper respiratory tracts. The most common respiratory disorders (apart from TB) are pneumonia, 
chronic obstructive pulmonary disease (COPD), Asthma, Bronchitis, Emphysema, and Cystic 
Fibrosis. These diseases have similar aetiologies making diagnosis difficult, particularly in resource 
limited settings.  
These common or overlapping symptoms such as fever, cough, dyspnoea, wheezing or chest pain, 
make the diagnosis of each particular disease challenging [4], [82], [83]. A study performed by 
Miravitlles et al, 2013, assessing COPD patients with mixed diseases was a notable example of this 








addition, some respiratory disorders such as COPD and TB share similar risk factors including 
diabetes, biomass pollution, smoking and nutritional status [32], [64], [84], [85]. Moreover the history 
of pTB is a potential risk factor to developing COPD, and vice versa [84], [85]. Early TB disease also 
has comparable symptoms and presentations as pneumonia [86]. Therefore, the development of a 
new TB test must be able to discriminate between TB and ORD (i.e. must be specific). WHO target 
product profile (TPP) requires >98% specificity and sensitivity for TB diagnostic tests (Table 1.1). 
 
Table 1.1 WHO recommend target product profile (TPP) performance characteristics for screening 
and diagnosis of TB 
  











 80% (compare to 
culture)  
 60% (smear negatives) 
 99% (smear positive) 








 ≥ 98% for pTB (smear 
positive/culture positive) 
 ≥ 68% (smear negative/ 
culture positive) 





















 Overall > 90% 
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Sens= sensitivity; spec=specificity; pTB= pulmonary tuberculosis; HIV = human 








 Tuberculosis Diagnosis  
The diagnosis of TB includes knowing the patient clinical history, chest radiography and 
bacteriological confirmation [87], [88]. Though there are many new TB diagnostic tests in the 
pipeline, sputum smear microscopy, GeneXpert and sputum culture are still the main tools of TB 
diagnosis, despite various problems associated with each.  
 Clinical Investigation 
Making a fast and correct diagnosis of tuberculosis is actually vital both for the patient and healthcare 
provider, to initialise early treatment and proper patient management. Thus, when a patient shows 
up at a health facility with symptoms suggestive of TB disease, the first thing the healthcare provider 
does is to subject the patient to a physical examination. This is done through the assessment of 
signs and symptoms of tuberculosis via interrogation about personal and family medical history. This 
includes assessment of any close contact to an active TB patient to establish the cause of the 
disease and length of exposure. Signs of TB include a continuous cough for more than two weeks, 
loss of appetite and weight, fever, sweat a lot in the night, coughing of blood, short breath and chest 
pain. This method of diagnosis is non-specific and extremely difficult in patients who may be suffering 
from EpTB, as symptoms may overlap with other conditions like spinal anomalies. Where there is 
no laboratory tests available, the patient may be put on antituberculosis treatment, with response to 
treatment the only confirmatory presence of the disease [89].  
 Radiological Investigation  
Imaging plays a crucial part in the medical diagnosis of TB and subsequent patient management. 
Chest radiograph (CXR) is key in the diagnosis and classification of individuals suspected to have 
TB [90]. It is a rapid method for identifying lung abnormalities[91], assessing treatment response and 
detecting disease complications. Although CXR has high sensitivity for active TB and is 
recommended as a triage or screening test, it is not specific, so it cannot be used independently  but 
with a confirmatory bacteriological test required [91] [92]. The impact of HIV co-infection, use of poor 
quality films, lack of expertise in reading the films, delay in diagnosis and sex of patients have all 
negatively impacted on the sensitivity and specificity performance of CXR [91] [93]. Digital 
radiography and portable diagnostic devices or computed tomography (CT) have been trialled  too 
[91].  Some of these methods were noted to be more sensitive and detected more bacterial activities 
than standard CXR.  Nevertheless, these methods are not widely supported due to infrastructure 








aided detection (CAD) software. This system will help mitigate variability between readers, thus 
reducing turnaround time for a CXR result, simultaneously taking care of the scarcity of skilled 
personnel. Even with the advantage associated with CAD, no recommendation has currently been 
given by WHO for its use due to limited data to assess it accuracy [91].  
 Sputum smear microscopy (SSM)  
SSM was established about one hundred years ago and still continues to be the bedrock of TB 
testing in least resource areas [87], [94], [95]  It is cheap, simple and requires minimal laboratory 
infrastructure.[96] SSM is very specific in TB-endemic settings[97] but has low sensitivity of between 
20-80% [18], [86], [98]. Sensitivity is lowest in sputum smear with scarce bacilli such as childhood 
TB and HIV positive TB patients [18], [97]. It requires about 5000-10000 bacilli per millilitre to detect 
the organism in the sample specimen. The drawback in sensitivity associated with Ziehl-Neelsen 
(ZN) method, led to the introduction of fluorescence microscopy (FM) [95]. This test uses 
fluorochrome dye (e.g., auramine O or auramine-rhodamine) which is more user friendly, sensitive 
and faster.[86], [97] However, it is also associated with false positives, making the replacement of 
ZN with Auramine tricky [97].  Furthermore, the size of Mtb bacilli requires adequate training to 
consistently discriminate acid fast bacilli (AFB) from debris which could attribute to false positive 
results [87], [95]. The inability of SSM to discriminate the diverse species of MTB complex or detect 
resistance TB [86] has further prompted the called for a better TB diagnostic tool.  
 Sputum Culture  
Sputum culture is the benchmark on which TB testing are based [18]. It is highly sensitive and 
specific ((80-93) % and 98 % respectively).[99] It is approximated to be 100-fold more sensitive than 
SSM [87]. It is mostly used as a confirmatory test to SSM and also provides further drug susceptibility 
testing. A culture test is either performed on solid media (Lowenstein-Jensen method) or liquid 
(mycobacterial growth indicator tubes (MGIT) -Becton Dickenson). The time of obtaining a positive 
result depends on the bacterial load. Solid culture last 6-8 weeks (56 days) to yield a positive result 
while the MGIT takes shorter time (42 days), with similar times to obtain a negative result [100]–
[102].  
Though culture is currently the gold standard, it has many limitations – it is expensive, requires 
adequate infrastructure, is time-consuming, laborious and prone to contamination and also requires 
good quality sputum [96], [103]. Moreover, culture is a luxury in resource-limited settings resulting in 
reliance on SSM and clinical evaluation of presumed TB cases. In laboratories where culture tests 








patient management [88]. The inclination to put clinically presumed TB cases on treatment without 
bacteriological confirmation carries the risk of non-TB patients being exposed to toxic TB therapy 
and the tendency of resistance bug to emerge. And with the changing epidemiology of TB; the 
increasing MDR and or HIV co-infection, and overlapping of symptoms with other respiratory 
diseases, a better diagnostic test which can mitigate the limitations of SSM and culture would be a 
great add-on in the fight against Mtb.  
 Nucleic Acid Amplification Test (NAAT) 
In recent years, molecular based testing has emerged to be the main diagnostic tool for tuberculosis 
and drug susceptibility testing in resource-rich settings [88]. This molecular assay testing otherwise 
called nucleic acid amplification tests (NAAT) are now common and have the ability to detect a small 
bacteria genetic material as well as drug resistant Mtb directly in the specimen [104], [105]. The 
assays are rapid, sensitive and specific, significantly improving the time to treatment.[88] However, 
they are expensive and require significant infrastructure, thus limiting their use in basic healthcare 
facilities accessed by the majority of TB patients [105]. Furthermore, the performance of these 
assays largely depend on sample collection method, volume and processing [106].The need for a 
well-trained individual and well equipped laboratory to perform the assay is a must requirement. In 
addition, NAAT assays varies in accuracies across studies, with reproducibility challenge, thus its 
recommendation as a replacement of culture is not likely [107]. Moreover, the presence of inhibitors 
could affect the outcome[108]. Though NAAT assays have been shown to be very sensitive (90-
100%) and specific (71-96%) on sputum smear positive respiratory samples, sensitivities dropped 
to (22 - 89%) while specificities are still good (97- 99%) in sputum smear-negative samples. For 
example, GeneXpert MTB-RIF (Cepheid) an automated method which detects both MTBC and RIF 
resistance bugs directly in sputum samples within 2hr,[107], [109] has sensitivity of 98.2% sputum 
smear positive and specificity of 99.2% while on smear negative, sensitivities ranges from 72.5-
90.2% [110]. Although GeneXpert has a tremendous immediate patient and public health impacts 
such as earlier patient diagnosis and treatment,[111] the use of the tool in lower tier healthcare 
centres is still a problem. The cost of infrastructural maintenance[109] remains a challenging aspect 
of the assay, limiting its uptake in resource limited settings, despite being heavily subsidised by the 
Bill and Melinda Gates Foundation (BMGF). 
NAAT’s inability to differentiate dead from live bacteria also hinders identification of faster treatment 
responders who may benefit from a shorter treatment course [88], [96]. Due to these limitations, we 
still require a simple, affordable, rapid and accurate point of care (POC) test which drastically 








 Tuberculosis biomarkers  
 Biomarkers 
Biological biomarkers has been defined as “biological characteristics that can be objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention”[112]. A combination of these biomarkers 
is referred to as biosignature. The application of biomarkers in medical care spanned back to many 
decades, thus, is a common practice in medical care. With the limitations of the current TB diagnostic 
tests, researchers are looking into (host or pathogen specific) biomarkers as a possible solution for 
TB diagnosis. Biomarker diagnoses are known to be rapid, accurate and less expensive, most often 
requiring no or less infrastructure to perform or set up a test. An example of these are the malaria 
rapid test (RDT), pregnancy and HIV tests. Biomarkers can be characterised based on different 
parameters such as its application: 1) exposure 2) disease and 3) treatment response. Biomarkers 
are indicators of immune activities. Therefore, their importance as possible diagnostic markers 
cannot be overemphasised. They would be useful in predicting, monitoring and testing the state of 
a disease or effectiveness of an intervention. Of recent, studies are looking into how biomarkers can 
be utilised to aid personalised medicine for instance cancer treatment. Thus, finding a sputum based 
markers would likewise aid the diagnosis of pulmonary tuberculosis, subsequently impacting 
positively in the reduction of transmission and disease mortality. Such a potential biomarker should 
safe and easy to measure, modifiable with treatment and consistent across gender, age and ethnic 
groups. At the moment, the only marker of tuberculosis disease is the detection or isolation of Mtb 
bacilli or its product in the sputum or urine of the host. With culture positive conversion to culture 
negative sputum the only marker of treatment response. The roadblock with this procedure of 
disease diagnosis is suboptimal performance of the current diagnostic methods in combination with 
the number of bacilli in the sputum. Therefore, exploration of the host markers in sputum which is 
the ideal representative sample of the site of infection or disease might provide a solution. Thus is 
the aim of this study.  We have previous shown in the pilot study, a combination three markers 
correctly classified TB by 96%.   
 Immunological biomarkers of TB 
Previously, diagnosis of tuberculosis infection relied on a century old test called tuberculin skin test 
(TST), a protein – purified protein derivative (PPD) extract from Mtb. The protein is injected 
intradermally into the forearm and the monitored for 48 -72 hours, then the induration is measure. 








as the age, nutrition and immune competency of the patient. The estimated cut-off of a TST result 
ranges between 5 -15mm, which also depends on the prevalence of disease, HIV status, age or 
medical history of the participant [113].  Furthermore, BCG vaccination or the prevalence of NTM, 
can affect a TST result due to shared proteins between the TST and BCG or NTM. Moreover, TST 
cannot differentiate active TB from LTBI. Thus, leading to introduction interferon gamma release 
assay (IGRA), a blood-based assay, which relies on the IFN-ү release by the stimulation of whole 
blood or PBMC with Mtb specific antigens – 6kDa early secretory antigenic target (ESAT-6) and 
10kDa culture filtrate antigen (CFP-10). There are two commercially available assays that utilised 
these antigens: Enzyme linked immunosorbent assay (ELISA) which measures IFN-ү release into 
plasma (QuantiFERON®-TB gold test (Cellestis Ltd., Australia)) and (Enzyme linked immunosorbent 
spot (ELiSpot) T-SPOT-TB assay (Oxford Immunotec, UK), which quantifies isolated peripheral 
blood mononuclear cells (PBMC) that releases IFN-ү. IGRA has comparable sensitivity to TST, 
however, it is more specific and not affected cross reactivity with either NTM or BCG. But the 
setbacks for IGRA are, it is an overnight stimulation assay, thus limiting it use as a POC and secondly 
it does not differentiate active TB from LTBI. Therefore, alternative markers are required in order to 
develop a test that is rapid, cheap and able to: 1) differentiate active from ORD, 2) monitor treatment 
response and 3) predict relapse.  
Recently, WHO has recommended a new commercial diagnostic test for TB (TB-LAM) (Alere Inc. 
Waltham, MA, USA), that uses lateral flow strip (non-laboratory based) to diagnose TB within 30mins 
[114], [115]. The AlereLAM test is an immunoassay that detect a traces of the mycobacteria - 
Lipoarabinomannan (LAM) in urine of adult active TB [114], [116]. The test was found to be more 
relevant among active TB cases living with HIV, particularly advanced AIDS patients with low CD4 
numbers, approximated to 100cells/µl than HIV negative TB patients [114]. A randomised control 
trial has shown reduced deaths among hospitalised TB cases by 17% [116], [117] prompting WHO 
to recommend for it used among TB/HIV+ and severely ill HIV patients[118]. It was also noted that 
the TB-LAM detect more individual with TB in patients with lowest CD4 numbers [115], [119]. A five-
study systematic review showed the sensitivity and specificity of TB-LAM among patient with CD4 
cell ≤200µl to be (50 and 90) percent respectively [116], [117]. Recently, a new TB-LAM diagnostic 
test developed by FIND and Fuji called the Fujifilm SILVAMP TB LAM (FujiLAM; Fujifilm, Tokyo, 
Japan) has also been shown diagnosis TB/HIV+ patients. Studies have shown FujiLAM to be more 
sensitive than the WHO approved AlereLAM [115], [118]. The FujiLAM test uses an 
immunochromatography silver halide amplification technology to improve the test control line 
visibility thus improving sensitivity but taking longer to generate results compared AlereLAM [118].  








individuals. not many countries currently include LAM as part of their TB national control programme 
[116] 
While TB mainly affects the lungs, researchers are looking for alternative sample types for non-
invasive and non-hazardous diagnosis. These include serum, plasma, culture supernatants and 
urine.  A biomarker is a protein in the body that indicates a normal or abnormal condition [76] 
whereas, a bio-signature is a combination of biomarkers. Many researchers have reported possible 
biomarkers or signatures for TB. Studies that utilised stimulated blood samples have reported finding 
many biomarkers or biosignatures that have the potential to distinguish TB disease from either 
latently infected, ORD or healthy controls. For example, in a study done by Chegou et al in 2013 
analysing QFT-GIT supernatants, they found IFN-α2, IL-1Ra, IP-10, sCD40L, IFN-γ, VEGF, TGF-α 
and EGF to differentiate children with TB from those  Mtb infection [120]. In a similar study by the 
same group comparing QFT-GIT supernatants of TB case and their close contacts, MIP-1β showed 
potential as a single marker to differentiate TB from LTBI, whereas a combination EGF with MIP-1β, 
sCD40L, IL-1α or VEGF or a three-marker signature (EGFNil, MIP-1βAg-Nil and IL-1αNil (or IL-1αAg) all 
showed promised to discriminate TB and LTBI as a biosignature [121].  The group did a follow up 
seven-day TB antigen stimulation and showed EGF and TGF-α as potential markers of TB [122] 
while a multisite  QFT-GIT data showed a four-marker signature (IFN-ү(NIL), TGF-α (NIL), IL-1rα (Agn) 
and MIP-1β(Agn) discriminated TB from ORD with 71% sensitivity and 81% specificity [123]. Since 
overnight stimulations are a hurdle to developing a rapid point-of-care test, researchers have now 
turned their focus to ex vivo sample types.  In plasma study IL-6, IP-10, TNF-α, sCD163 and sCD14 
were found to be higher in TB compared to LTBI or healthy controls but this study did not include an 
ORD group [124].  Another study looking at serum found a 6-marker combination of NCAM, SAP, 
IL-1β, sCD40L, IL-13 and Apo A-1 could discriminate TB from ORD with a sensitivity of 100% and a 
specificity of 89%, increasing to 100% if HIV positive subjects were excluded [125]. In another study 
IL-1β, IL-23, ECM-1, HCC1 and Fibrinogen in saliva discriminated TB from ORD with a sensitivity of 
89% and specificity of 90%, and an eight-marker signature resulted in a sensitivity of 100% and 
specificity of 95% [126]. Though the results were very good, the author caution that this was a 
discovery phase and the sample size was small, thus confirmatory studies should be done. Similar 
studies were also carried in our laboratory  in which Sutherland et al (2012) found a three-marker 
signature (IP-10, IL-6 and IL-10) which classified pleural TB from ORD with 96% accuracy [127]. The 
same laboratory showed a combination of IL-13, FGF and IFN-ү in ex vivo sputum resulted in 96% 
specificity and 85% sensitivity [128]. Furthermore, a multisite  collaboration, which included MRCG 
at LSHTM, showed promising results with a seven-marker serum signature of CRP, transthyretin, 








serum amyloid A) discriminating TB from ORD  with a sensitivity of 93.8% and 73.3% specificity 
[129]. A follow up study was conducted utilising a finger prick lateral flow test strip to evaluate the 
six of those marker (IL-6, IP-10, CRP, SAA1,Ferritin and ApoAI), with promising data on three 
markers (IP-10,SAA1 and CRP) which are now under further evaluation for future use in basic 
healthcare centres as a triage test.  
 Immunodiagnostic triage tests 
New immunodiagnostic tests are currently being developed such as acute phase protein that is 
shown to increase and decrease rapid during and after an infection or in the course of treatment 
especially for children [90]. However, it has limited specificity for TB on its own. Another marker that 
is under investigation for use in diagnosis of TB or TB treatment response is IP-10 [90], [91].  
Numerous studies in various settings showed IP-10 to be highly increased in TB patients compare 
to non TB controls (LTBI, ORD or Healthy) even without stimulation as reviewed by  Ruhwald et al 
(2012) [92] and reported by other people [93]. This marker was also among the recently discovery 
signature (seven-marker biosignature) [94] translated to a user friendly lateral flow device to 
discriminate TB among other respiratory diseases in our laboratory and our collaborators’ 
laboratories [95]. A 3-gene signature was also identified as promising signature for screening TB as 
well treatment response, thus a potential replacement for sputum conversion marker at 2 months. 
The same author has claim that the signature is able to discriminate TB from LTBI or healthy control 
regardless of HIV status [96].  Although many of the tests have inadequate diagnostic performance, 
some of them show potential to be used as screening or triage test as per the WHO recommendation 
for a screening or triage test, which requires sensitivity >90% and specificity >70% [97] (Table 1.1) 
One important requirement for a triage test is a high sensitivity in order to identify as many cases as 
possible [90]. A test should be affordable and obtain results within a short time (<20) mins. Moreover, 
for a triage test to be effective, those who are pronounced positive, should proceed to a confirmatory 















 Treatment and treatment response  
 Treatment 
The treatment for presumed susceptible TB  last  six months [130], however, with slow responders, 
treatment could be extended. Treatment is also much longer (15-20) [131] months for individuals 
have multiple drug resistant TB or extremely drug resistant TB. The consequence of late diagnosis 
and  prolong initiation of treatment is death with an estimated 70% of untreated smear positive Mtb 
case dying [132]. Inappropriate or ineffective TB treatment could result in longer treatment duration 
and potential development of resistant TB or even a relapse of the disease. TB treatment regimen 
requires a combination of multiple anti-tuberculosis drugs [isoniazid (INH), rifampin (RIF), 
pyrazinamide (PZA), ethambutol (EMB) and streptomycin (SM)] and in two phases - the intensive 
and continuation [133], [134]. The intensive phase lasts for 2months and includes four drugs - 
isoniazid, rifampicin, pyrazinamide and ethambutol. The continuation phase lasts for 4 months and 
consists of isoniazid and rifampicin [134], [135].  
 Treatment response  
Tuberculosis treatment response monitoring poses similar challenges as TB diagnosis due to 
reliance on pathogen detection. Currently the only accepted marker for treatment response is a 
culture positive sputum conversion to negative [136] but the challenge is its predictive ability is low 
aside, the limitation associated with culture and smear microscopy.  Of recent, a Mycobacterial  load 
assay has been developed with a great potential to be used as treatment monitoring technique, it 
detects mainly the viable bacilli through detection of  16S rRNA [137]. However, it is tedious, 
expensive and requires skilled personnel to perform the procedure. Thus, various studies are looking 
into host immunological markers for potential TB diagnosis or treatment response monitoring. Many 
studies have also reported the essence of immunological markers in future TB diagnosis and 
treatment monitoring, hence more studies are focusing in this area of research.  Previous Flow 
Cytometry based studies  have shown  early immune based markers such as CD38 and HLA-DR 
and proliferation Ki67 expression on Mtb specific CD4+ to be ideal markers of TB treatment response 
[138], [139]. Equally, IL-10 and MIP-1α were also found to higher among TB cases who showed slow 
response to antituberculosis treatment [140], IL-10 a cytokine known to impede bacteria clearance, 








phagocytic cells to site of infection [142], thus suggesting these cytokine are potential indicator of 
disease burden. Their presence in high concentration may also suggest prolong treatment [140]–
[142]. A transcriptomic study also reported a 3-gene TB score with the potential to monitor treatment 
outcome [143], while a positron emission tomography and computerized tomography (PET-CT) 
images showed the presence of  lesions and MTB mRNA – Alpha-crytallin (hspX)  to be linked to 
persistence MTB in the host even after completion of treatment [144]. A study done on saliva 
reported a combination of IL-17A, IL-23 and ECM-1 to be good indicators of treatment responses 
when TB cases were compared to other respiratory disorders [126]. Many studies have also found 
CRP, SAP, IP-10 and VEGF to be good indicators to monitor TB treatment [125], [145], [146]. 
Although, studies have reported identifying potential markers of TB treatment, the challenge is how 
to escalate this finding to a POC test. Aside, many of these used different, patient groups, sample 
type, technique and also in in different geographical area.  
 Project aims and objectives 
The aim of this project is to profile a broad array of host markers for development of optimal 
biosignatures for detection of pulmonary tuberculosis from other respiratory disorders using ex vivo 
sputum samples.  
 Specific Objectives  
 To determine optimal signatures in ex vivo sputum for diagnosis of sputum and culture 
positive TB patients  
 To determine optimal signatures for diagnosis in difficult patient groups including: 
- Smear negative but culture positive TB patients 
- HIV co-infected TB patients  












 Materials and Methods 
 
 Ethics approval  
Ethical approval was given by the MRCG at LSHTM/Gambian government joint ethics committee. A 
written informed consent was done before the initiation of the project. For participants <10 years, 
consent was given by their legal guardian or parents while those above 10 year personally agreed 
to join the study. The ethic approval code for this project was SCC1333 
 
 Study participants and setting 
 
Study participants were recruited from patients who were seeking medical attention at the MRCG at 
LSHTM outpatients department and the Tuberculosis clinic with symptoms associated with TB, prior 
to clinical or microbiological diagnosis. Upon written informed consent, sputum samples were 
collected at baseline from all participants and at 1 month and 2 months from those who were 
subsequently found to have TB. The collected sputa were then transported in a cold box at 4-8oC to 
the TB Diagnostic (TBD; 5 minutes’ walk from the clinic) where the samples were processed. At the 
TBD laboratory, the temperature and sample information were verified and logged to a sample book 
in the TBD laboratory. Microbiological tests (smear microscopy and/or culture and/or GeneXpert) 
were performed on all subjects. Participants who were smear negative without any further 
confirmatory tests had mycobacterial load assay (MBLA) performed to confirm the results as 
described in section 2.4. The participants were then classified as either having TB or other 
respiratory disorders (ORD). The clinical information for the participants were entered into our MRCG 
at LSHTM database.  
 Current microbiology test procedures  
 Liquid culture procedure  
Once the samples were received in TBD laboratory and registered, a portion of each sample was 
aliquoted into the 50ml falcon tube. An equal volume of N-Acetyl-L-Cysteine–Sodium hydroxide 








containing the sample. The falcon tube was then tightly closed, the solution in the tube mixed by 
swirling on the shaker for 5sec. Then incubated for 15mins at room temperature (RT). Following the 
incubation, the sample was centrifuged at 3000xg for 20mins, with centrifuge set at aerosol-free and 
refrigerated, with sealed buckets. Following the centrifugation, the sample was allowed to settle for 
5mins, then the supernatants harvested and discarded into a jar containing concentrated hycolin or 
phenolic disinfectant. While 0.5ml of sediment was transferred into the Mycobacteria growth indicator 
tube (MGIT BBL tube, 7mL) containing 2ml of 50% glycerol (sterile phosphate buffer – PH 6.8). Prior 
to the transfer of sediment, the MGIT PANTA Antibiotic was reconstituted with 15ml BACTEC MGIT 
Growth Supplement. An aliquot of 0.8ml of the reconstituted growth supplement was then transferred 
into the MGIT tube followed by the addition of 0.5ml of sputum sediment. The MGIT tube was then 
tightly closed and mixed by inverting the tube several times. Next the tube is wiped dry, scanned and 
inserted into BACTEC MGIT 960. The temperature is regulated close to 37oC. The tubes were left 
in the instrument until flagged positive but after six weeks, all samples that the instrument has not 
flagged up, were considered instrument negative.  An acid fast bacilli (AFB) and subculture were 
then performed on the instrument positives as a confirmation Mtb presence.  All steps were carried 
out in biological safety cabinet (BSC) level III in a contained facility. 
 GeneXpert (XpertMTB/RIF) procedure  
An aliquot of one millilitre of the collected sputum was transferred into a 15ml falcon, next 2ml of 
sample reagent was added. The sample mixture was gently shaken by inverting the falcon tube 20 
times. The sample was then incubated for 10mins at RT, followed by another gentle shake. After 
which an aliquot of 2ml diluted sample was transferred to the XpertMTB/RIF cartridge, then scanned 
to identify the module to insert the cartridge.  Once the cartridge was inserted, the run would last 
2hr.  The results generated from XpertMTB/RIF assay was either Mtb detected as (high, medium, 
low or very low) or Mtb not detected. The assay also generated cycle threshold (bacterial load) as 













 Mycobacterial load assay   
 Sputum digestion 
An aliquot of sputum was digested with Sputolysin (1mg/ml, Merck Millipore, USA) at 1:1 dilution, 
then vigorously vortexed and incubated for 15 mins at room temperature (RT).  After the incubation, 
the samples were centrifuged at 2000rpm for 10mins. The supernatants for Luminex analysis were 
harvested into sarstedt tubes, while pellets for MBLA analysis were re-suspended in 1ml of trizol 
(ThermoFisher, UK). Both tubes were stored in -80oC for later use. 
 RNA extraction 
Pellets stored in trizol were thawed and 2µl of a 560 RNA extraction control (Bioline Reagents Ltd, 
UK) was spiked into the thawed samples. RNA extraction was performed using Qiagen RNeasy Mini 
Kit (250) (Qiagen, Germany). Two hundred microliters (200µl) of chloroform was added to the thawed 
samples, vigorously mixed and incubated for 10mins at RT. Samples were then centrifuged at 
13000rpm for 15mins at 4oC. The upper aqueous phase was harvested, an equal volume of 70% 
ethanol was added and vortexed.  The 700µl of the mixed solution was transferred to RNeasy-
MinElute Spin Columns (Qiagen, Germany) and centrifuged for 15 sec at 10,000 rpm. The flow-
through discarded and flow-through collection tube re-used. This step was repeated if the volume of 
mixed solution was more than 700µl. Next 350µl of RW1 buffer was added into the RNeasy-MinElute 
Spin Columns, then incubated for 5mins at RT, followed by another 15 sec at 10,000 rpm spun. The 
flow-through was discarded, the RNeasy-MinElute Spin Columns was then inserted into a new flow-
through collection tube. 80µl of DNase master mix (10µl DNase plus 70µl RDD buffer) was added 
into the RNeasy-MinElute Spin Columns, incubated again for 15mins RT. Following the incubation, 
350µl of RW1 buffer was added, spun for 15 sec at 10,000 rpm. The flow-through was discarded, a 
500µl of diluted RPE buffer (1 part of RPE to 4 parts of 100% ethanol), spun for 2mins at 10,000rpm, 
this step was repeated, then flow-through discarded. The RNeasy-MinElute Spin Column was then 
transferred into a new collection tube and centrifuged at full speed (13,000 rpm) for 5mins. To elute 
the RNA, the RNeasy-MinElute Spin Column was transferred to a storage tube (eppendorf), a 30µl 
of elution buffer was added and spun for 2 mins at 13,000 rpm. This step was done twice to collect 
two 30µl aliquots of eluted RNA, which were stored at -80oC until processing.  
 H37Rv Standard preparation 
800μl of growth supplement and 500μl of Mtb (H37Rv) stock were added to a mycobacteria growth 
indicator tube (MGIT). The tube was then placed in the BACTEC (Becton Dickinson, USA) machine 








500μl of Mtb cell suspension for 2 weeks in a 37oC, 0.05% CO2 incubator. The optical density (OD600) 
was determined every 2 days using a spectrophotometer alongside single colony forming unit (cfu) 
counts to confirm growth curves.  When an OD of 2.2 was reached, 1 ml of Mtb suspension was 
aliquoted and stored in an equal volume of trizol at -80oC for later use. To generate a standard curve, 
a serial dilution of one aliquot of Mtb suspension was performed, then plated on 7H9 agar plate, and 
20µl of each serially diluted vial was plated on 7H11 at 3 different spots. These were then incubated 
for 3 weeks with a visual count of cfu performed every 2 days. RNA was then extracted and qRT-
PCR was used to run the standards targeting the 16S rRNA of MTBC. The value for the top standard 
was estimated at 108 cfu.  
 16S RNA analysis  
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to determine the 
level of viable bacteria (16S rRNA) in the extracted sputum pellets. A SensiFAST Probe No-ROX 
One-Step Kit (Bioline, Reagents Ltd, UK) was used to perform the assay. A master mix containing 
12.5μl 2x SensiFast Master Mix, 6.75μl of nuclease free water, 0.2μl reverse transcriptase, 0.4μl of 
RNase inhibitor, 0.05ul of 10uM (16S Rox Probe, forward primer and reverse primer) was used for a 
single reaction.  In addition, 5µl of RNA sample, standard or nuclease free water was added to their 
appropriate wells in a 96 well plate containing the 20µl of reaction mix for a total volume of 25µl. The 
plate was briefly vortexed and centrifuged at 10000rpm for 1min. A QuantStudio qPCR 7 plex system 
(Applied Biosystems, UK) was used to run the assay at the following thermal cycling parameters: 1 
cycle at 45oC for 20mins and 95oC for 10mins followed by 40 cycles at 95oC for 10sec and 60oC for 
45sec. The results were analysed with ABI7500 software version 2.3 (Applied Biosystems, UK).   
 Multiplex Immunoassay  
Using the Luminex platform, three multiplex immunoassays were performed for each sample. 1) a 
27-plex Bio-Plex Pro™ Human Th1/Th2 Cytokine Panel from Bio-Rad (Belgium) with analytes: IL-
1β, IL-1rα, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL-15, IL-17A, Eotaxin, FGF-
basic, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α and 
VEGF. 2) a Bio-Plex ProTM Human inflammation panel I/II 37-plex  kit (Bio-Rad, Belgium) with 
analytes: APRIL/TNFSF13, BAFF/TNFSF13B, sCD30/TNFRSF8, sCD163, Chitinase 3-like 1, 
gp130/slL-6Rβ, IFN-α2, IFN-β, IFN-ү, IL-2, slL6Rα, IL-8, IL-10, IL-11, IL-12(p40), IL-12(p70), IL-19, 
IL-20, IL-22, IL-26, IL-27(p28), IL-28A/IFN-λ2, IL-29/IFN-λ1, IL-32, IL-34, IL-35, LIGHT/TNFSF14, 
MMP-1, MMP-2, MMP-3, Osteocalcin, Osteopontin (OPN), Pentraxin-3 (PTX), sTNF-R1, sTNF-R2, 
TSLP and TWEAK/TNFSF12. 3) MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead 








EGF, Eotaxin, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, 
IL-1rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, 
IP-10, MCP-1, MCP-3, MDC, MIP-1α, MIP-1β, TGF-α, TNF-α, TNF-β and  VEGF.  
 We opted for these three immunoassays because in the first place the pilot study that led to this 
current study was performed with 27-plex. The results from that study were encouraging, moreover, 
we discovered ex vivo host markers in sputum were higher when compared to serum or saliva. So 
we sticked with the 27-plex kits and added the 37-plex which contains some cytokines of interest 
such as the type I interferons. Finally, the inclusion of the Millipore kit was based the collaborative 
work performed with SUN immunology research group using culture supernatant. We found the 
markers in the Millipore panel to have performed well in classifying TB and ORD, hence, we opted 
to try the panel the current study.  
The experiments were performed according to the manufacturers’ specific protocols however, the 
beads and detection antibodies were diluted 1:1 as previously optimised in our laboratory. Following 
sample preparation, the specific immunoassay procedures were performed as described in the 
sections 2.4.1 and 2.4.2 below. 
 Bio-Rad immunoassay procedures – 27 and 37-plex assays  
The lyophilised standards and controls were reconstituted with standard diluent (27-plex 500µl, 37-
plex 781µl and control 250µl) and kept on ice for 30mins.  After the incubation, the reconstituted 
standard was serially diluted to 8 standard points. While the reconstituted standards/control were 
incubating on ice, the coupled beads were sonicated for 30sec, vortexed briefly and reconstituted 
with assay buffer. 50µl per well of the reconstituted beads was added to the assay plate and then 
washed twice with 100µl per well of 1x diluted wash buffer. Followed by an addition of 50µl per well 
of samples, blank, controls and serially diluted standards to the appropriate wells (Fig. 2.1). The 
plates were incubated in foil for 30mins (27-plex) or 1hr (37-plex) on a rocking platform at 850rpm at 
RT. Following the incubation, the plates were washed, 25µl detection antibody added and incubated 
as above for 30mins. At the end of this incubation, another wash was done, then 50µl of Streptavidin-
PE was added, incubated for 10mins, washed and 125µl assay buffer added. The plates were 
shaken briefly and read. All washes were done using a magnetic wash station (Bio-Rad, Belgium). 
The Magpix was used to read the plates and Bioplex Manager (MP 6.1) software was used to analyse 
the data. Standards from plate 1 were imported to plate 2 for analysis (Fig. 2.1). The range of the 
serially diluted standards (Top and lowest) and controls for 37-plex are outlined below. (Table 2.1, 








Table 2.1.  The 27-plex kit standard range  
  Standard Ranges  (pg/ml) 
Marker  Top standard value Lowest standard value 
IL-1β 3992 0.24 
IL-1-rα 41240 2.52 
IL-2 24962 1.52 
IL-4 2985 0.18 
IL-5 70064 4.28 
IL-6 11177 0.68 
IL-7 29961 1.83 
IL-8 18289 1.12 
IL-9 33284 2.03 
IL-10 27336 1.67 
IL-12(p70) 27162 1.66 
IL-13 10111 0.62 
IL-15 169961 10.37 
IL-17A 41474 2.53 
Eotaxin 5472 0.33 
FGF-Basic 54963 3.35 
G-CSF 150626 9.19 
GM-CSF 8975 0.55 
IFN-ү 18294 1.12 
IP-10 47181 2.88 
MCP-1 9456 0.58 
MIP-1α 2116 0.13 
MIP-1β 6935 0.42 
PDGF-BB 53904 3.29 
RANTES 36307 2.22 
TNF-α 68937 4.21 
VEGF 155565 9.49 
 
 








Table 2.2. 37-plex markers’ standard and control ranges  
  Standard and Control Ranges (pg/ml) 
Marker  Top standard value Lowest standard value,  Expected control range 
APRIL/TNFSF13 995390 455 40605 - 94744 
BAFF/TNFSF13B 347678 159 8458 -19736 
sCD30/TNFRSF8 18377 8 389 -930 
sCD163 617571 282 13860 - 32339 
Chitinase 3-like 1 107240 49 2313 -5397 
gp130/sIL6Rβ 156594 72 3613 -8430 
IFN-α2 12219 6 255 -594 
IFN-β 3069 1 62 - 146 
IFN-ү 15079 7 315 - 734 
IL-2 10223 5 198 - 462 
sIL-6Rα 36429 17 1339 - 3124 
IL-8 9100 4 138 - 323 
IL-10 6147 3 106 - 247 
IL-11 1262 1 29 - 67 
IL-12(p40) 18546 8 287 - 669 
IL-12(p70) 3139 1 63 - 147 
IL-19 20144 9 309 - 721 
IL-20 9819 4 239 - 557 
IL-22 26618 12 537 - 1253 
IL-26 103216 47 2019 - 4712 
IL-27(p28) 19964 9 551 - 1286 
IL28A/IFN-λ2 19087 9 403 - 939 
IL-29/IFN-λ1 21154 10 380 - 886 
IL-32 12104 6 409 - 953 
IL-34 102537 47 5149 - 12015 
IL-35 49763 23 1256 - 2930 
LIGHT/TNFSF14 8293 4 195 - 455 
MMP-1 226295 103 5093 - 11883 
MMP-2 439914 201 10752 - 25088 
MMP-3 413108 189 7809 - 18222 
Osteocalcin 149899 69 3031 - 7071 
Osteopontin(OPN) 301476 138 8750 - 20417 
Pentraxin-3 72713 33 3525 - 8226 
sTNF-R1 49154 22 941 - 2195 
sTNF-R2 19939 9 400 - 933 
TSLP 2085 1 36 - 83 
TWEAK/TNFSF12 12292 6 198 - 463 
 
 








Figure 2.1: Plate layout for Bio-Rad Human Cytokine/Chemokine kits Lot#……  
Plate1:                      Date: ………………..……………………………… 
 1 2 3 4 5 6 7 8 9 10 11 12 
A STD 1 STD 1           
B STD 2 STD 2           
C STD 3 STD 3           
D STD 4 STD 4           
E STD 5 STD 5           
F STD 6 STD 6           
G STD 7 STD 7         QC QC 
H STD 8 STD 8         BLK BLK 
 
 
Plate 2: import standards 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G           QC QC 
H           BLK BLK 
 
The most concentrated standard is STD1 and the least is STD6 










 Milliplex MAP immunoassay procedure – 38-plex assay 
The lyophilised standard and controls were reconstituted with 250μl distilled water each, then 
incubated for 10min at RT.  The reconstituted standard was serially diluted to 6 standard points 
(10,000, 2000, 400, 80, 16, and 3.2) pg/ml, with 0pg/ml of assay buffer as blank. The premixed beads 
were sonicated, vortexed and diluted (1750µl of premixed beads into 3850µl of bead diluent). 50µl 
of the diluted beads was then added to the immunoassay plate and washed. 25μL of serially diluted 
standard, control, blank or samples were added to the appropriate wells as outlined in the plate map 
below (Fig. 2.2). Followed by another addition of 25µl of sample matrix into the blank, standard and 
control wells, while 25µl of assay buffer was added to the sample wells. The plate was then sealed 
and wrapped with foil.  The wrapped plate was then incubated for 2hr at 850rpm at RT. After 
incubation, the plate was washed twice, 25µl of diluted (3200µl of concentrated detection antibody 
plus 2400ul of assay buffer) detection antibodies added, plate sealed rewrapped and placed on a 
shaker at the same incubation conditions for 1hr.  Following the 1hr incubation, 12.5µl of 
Streptavidin-PE added, incubated again for 30mins. A final wash was done, 80µl of sheath fluid 
added and rocked for 5mins.  All washes were done using a Magnetic wash station. The Magpix was 
used to read the plates while Bioplex Manager (MP 6.1) was used to analyse the data. Standards 
from Plate 1 were imported for Plate 2 analysis (Fig. 2.2). However, one standard curve was used 
to extrapolate the data for all the markers, but, each marker had its own control ranges as outline in 
Table 2.3. 
Table 2.3. The range of controls for 38-plex markers  
 
Control range (pg/ml) 
Marker  QC 1 QC2 
EGF 103 - 215 479 -994 
Eotaxin 98 - 203 448 - 931 
FGF-2 75 - 156 374 - 777 
Flt-3L 101 - 210 497 - 1033 
Fractalkine 112 - 232 501 - 1042 
G-CSF 115 - 240 557 - 1158 
GM-CSF 91 - 190 447 - 928 








IFN-α2 88 - 184 430 - 894 
IFN-ү 93 - 193 467 - 969 
IL-1α 111 - 230 492 - 1021 
IL-1β 89 - 185 425 - 883 
IL-1rα 80 - 167 366 - 761 
IL-2 93 - 194  461 - 957 
IL-3 105 - 219 501 - 1040 
IL-4 92 - 192 455 - 945 
IL-5 114 - 238 513 - 1065 
IL-6 104 - 216 512 - 1063 
IL-7 98 - 204 489 - 1017 
IL-8 101 - 209  459 - 952 
IL-9 113 - 235 527 - 1095 
IL-10 108 - 224 528 - 1098 
IL-12(p40) 108 - 225 549 - 1141 
IL-12(p70) 120 - 248 565 - 1174 
IL-13 111 - 230 544 - 1131 
IL-15 96 - 200 465 - 965 
IL-17 101 - 211 489 - 1017 
IP-10 90 - 186 462 - 960 
MCP-1 105 - 217 503 - 1044 
MCP-3 109 - 227 490 - 1018 
MDC 135 - 281 649 - 1349 
MIP-1α 136 - 282 746 -1549 
MIP-1β 88 - 183 450 - 935 
sCD40L 83 - 172 478 - 993 
TGF-α 94- 195 407 - 846 
TNF-α 92 - 192 472 - 981 
TNF-β 111-230 515 - 1070 













Figure 2.2: Plate layout for MAP Human Cytokine/Chemokine kits Lot#…………  
Plate1:                                                                            Date: ………… 
 1 2 3 4 5 6 7 8 9 10 11 12 
A STD 1 STD 1           
B STD 2 STD 2           
C STD 3 STD 3           
D STD 4 STD 4           
E STD 5 STD 5           
F STD 6 STD 6           
G QC1 QC1           
H QC2 QC2         BLK BLK 
 
 
Plate 2: import standards    kits Lot#…………………..Date: ………………..……………… 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G QC1 QC1           
H QC2 QC2         BLK BLK 
The most concentrated standard is STD1 and the least is STD6 












 Statistical Analysis 
Statistical analyses and graphs were generated using R – statistics (https://www.R-project.org/) and 
GraphPad Prism version 8.0.2 (Software MacKiev, USA) respectively. The median cytokine levels 
in TB and ORD groups were compared using the Mann–Whitney U-test, followed by multiple 
correction testing using Benjamin Hochberg test [147], [148]. Generalised linear multiple (GLM) 
regression analyses were performed and receiver operator characteristics curves (ROC) generated 
to assess the predictability and performance of the analytes in differentiating TB from ORDs. The 
performance characteristics and cut-offs for individual markers of the ROC analyses were generated 
using OptimalCutpoints-package version 1.1-4[149] in association with the Youden Index method. 
After performing single marker analyses, a combined marker analysis was done to evaluate the ideal 
biosignature for differentiating TB from ORD using multiple logistic regression. Prior to this, the data 
was randomly split into training and test datasets in a ratio 0.8 to 0.2.  Upon performing the multiple 
logistic regression, a multicollinearity of the combined markers analysed was verified using variance 
inflation factor (VIF)[150] in the car package version 3.0-3[151]. Then a backward and forward 
stepwise variable selection was performed, deleting non statistical significant variables or variables 
that showed no contribution to the model via Akaike information criterion (AIC). The built model was 
then applied to the test data to determine its performance in a new data in relation to the data in 
which the model was trained on.  Wilcoxon and Friedman tests were used to compare the individual 
host marker levels during the course of treatment, with a pairwise analyse done to assess the 
difference in the individuals who provided samples at three time points during the course of 











 Participant demographics 
A total of seven hundred and forty-one (741) participants were included in the analysis. Of these, 
428 were confirmed to have TB by microbiological tests (sputum smear, culture and/or GeneXpert), 
while 313 were confirmed to have other respiratory disorders (ORD). Participants who had ORD 
were not investigated further due to limited resources.  
For the confirmed TB group, 123 were positive by culture, smear and GeneXpert (Xpert), 167 were 
both culture and smear positive, 13(7.22%) were culture positive but smear negative, 75 were Xpert 
and culture positive, and 18 were Xpert and smear positive (Table 3.1). For the ORD group, only 61 
had only culture performed, of which 45 (73.78%) were negative and 16 (26.23%) were 
contaminated. We performed MBLA on 207 participants who were smear negative without any other 
evaluation. Of these, 32(15.46%) were positive by MBLA and thus classified as TB. The cycle 
threshold (Ct) values were obtained as an average of duplicate wells ran for each participant sample, 
while the quantity of the viable bacteria present was extrapolated from the standard curve. The 
highest standard point (top standard) had an estimated copy of 108 bacteria whereas the lowest 
was102 cfu/ml.  The cut-off Ct value was 36, any Ct value above the cut-off was considered negative.  
The median (interquartile range) of bacterial copy for the positive MBLA was 1441.79(291.2, 
15091.62) with a median (interquartile range) Ct of 30.3(27.40, 33.35) whereas the negative MBLA 
median (interquartile range) bacterial copy was 10.82(3.72, 17.69), with a median Ct of 40 (Table 
3.1A) also illustrated in figure 3.1.  
Of the confirmed TB cases, 29.91% were female compared to 47.6% of the ORD group. When the 
median ages of TB and ORD were compared there was a significant difference between the two 
groups, with a p value <0.0001. The median (interquartile range) was 31(23-43) years and 40(24-
56) years for TB and ORD respectively. There were 16 HIV co-infected TB patients and 4 HIV-
infected ORD patients. Of the confirmed TB/HIV co-infected, 13 were culture positive with 2 culture 
positive but smear negative. The 4 ORD were both smear and MBLA negative.  
40 children were also analysed: 17 were confirmed to have TB while 23 had ORD. Of the confirmed 
TB, 7 were positive for culture, Xpert and smear, while an additional 4 were double positive for culture 
and smear. MBLA was also done for 8 participants who had only a smear negative result, of these, 
2 were MLBA positive. The age range for the children was from 1-17 years. None of the children 









Table 3.1  Participant demographics 
Patient characteristics  TB  ORD  
n= 741 428 (57.76) 313 (42.24) 
Female (%) 128 (29.91) 149 (47.6) 
HIV infected (%) 16(3.73) 4(1.28) 
Children (<18 years) 17(42.5) 23(57.5) 
Median IQR age (years)  31(23-43) 40(24-56) 
Confirmed by microbiology tests: 
Smear, culture and Xpert 123 (28.74) 20 (6.39) 
Smear and culture 180(42.05) 42 (13.42) 
Culture and Xpert 75 (17.52) 42 (13.42) 
Smear and Xpert 18 (4.21) 34 (10.86) 




Table 3.1A   The quantity of viable bacteria RNA in the sputum of suspected TB patients 
MBLA Results  Bacteria  median (IQR) Cycle threshold  median(IQR) 
Positive 1441.79(291.2, 15091.62) 30.3(27.40, 33.35) 
Negative  10.82(3.72, 17.69) 40(40, 40) 
 




n= number, TB= tuberculosis, ORD= other respiratory disorders, 




















































 The Performance of individual host markers in diagnosis of TB 
disease 
Seventy (70) host markers were examined in total to assess their ability to distinguish TB from ORD. 
The median concentrations of host markers in sputum were compared using the Mann Whitney U 
test with post-test correction for multiple comparisons using Benjamini-Hochberg test[147]. We found 
32 markers increased significantly between TB and ORD patients. The majority of the markers were 
found to be higher in the TB group compared to the ORD group except G-CSF, IL-26, IL-3 and 
APRIL. Of these four markers (G-CSF, IL-26, IL-3 and APRIL), only APRIL showed a significant 
different (p-value =7.24E-08) in their median levels with a concentration of 1103pg/ml and 
118268pg/ml for TB and ORD respectively (Table 3.2B). When receiver operator characteristics 
(ROC) analysis was performed to determine the ability of each marker to differentiate TB from ORD. 
The most accurate single markers among the three kits were mostly found in the 27-plex kit. This 
included IL-1β (AUC=0.69, (95% CI: 0.64, 0.73) sens=71%(95% CI: 66, 76), spec=61%(95% CI: 55, 
67), FGF (AUC=0.69 (95 CI: 0.65, 0.73), sens=62% (95% CI: 56, 66), spec=70% (95% CI: 64, 75), 
GM-CSF (AUC=0.69 (95% CI:0.65, 0.73), sens=61% (95% CI: 55, 66), spec=73% (95% CI: 67, 78) 
and RANTES (AUC=0.68 (95% CI: 0.64, 0.72), sens=68% (95% CI: 63, 73), spec=65% (95% CI: 58, 
70)(Table 3.2A). Nonetheless, two markers in the 37-plex also performed well. That is BAFF 
(AUC=0.68 (0.95 CI: 0.64, 0.72), sens=82% (95% CI: 0.78, 0.86), spec=50% (95% CI: 44, 55) and 
MMP-2 (AUC=0.73(95% CI: 0.70, 0.77), sens=58% (95% CI: 52, 62), spec=81 %( 95% CI: 76, 85) 
Figure 3.1.  The cycle threshold (A) and quantity (B) of viable bacteria RNA in the sputum of 
suspected TB patients. qRT-PCR was used to quantify to perform the MBLA.  ORD= other 








(Table 3.2B). MMP-2 performed the best with an AUC of 0.73 (sens=58 and spec=81%) with a high 
concentration cut-off of 9273 pg/ml (Table 3.2B). The least performed markers were the 38-plex with 
MIP-1α been optimal performer with an AUC of 0.65, sensitivity of 53% and specificity of 70% (Table 
3.2C). The single best performed markers illustrated in figure 3.2.  
Table 3.2: Diagnostic performance of individual markers 

















    
IL-
12p70 
1.89 1.66 4.45E-03 55.05 58.8 0.66 0.47 1.67 
0.56 (0.52, 
0.60) 
IL-9 200.15 159.43 2.47E-04 84.6 32.21 0.65 0.59 85.92 
0.58 (0.53, 
0.62) 
IL-8 18066.83 12048.7 3.77E-05 62.37 54.68 0.67 0.5 13634 
0.59 (0.55, 
0.64) 
IL-15 324.87 209.79 2.55E-05 72 49.06 0.68 0.54 206.37 
0.59 (0.55, 
0.64) 
IL-13 12.94 6.94 9.71E-06 75.25 44.57 0.67 0.55 3.82 
0.60 (0.55, 
0.64) 
IL-6 34.315 14.41 3.39E-06 66.91 53.56 0.68 0.52 16.1 
0.61 (0.56, 
0.65) 





157.79 108.35 1.26E-07 36.36 79.78 0.73 0.46 210.72 
0.61 (0.57, 
0.66) 
Eotaxin 29.55 12.94 7.16E-08 67.42 54.31 0.69 0.53 15.45 
0.63 (0.58, 
0.67) 
IFN-γ 278.71 123.32 3.90E-09 66.16 59.17 0.71 0.54 172.88 
0.64 (0.59, 
0.68) 
IL-4 11.31 4.84 7.86E-11 64.64 61.42 0.71 0.53 7.7 
0.65 (0.61, 
0.69) 
IL-5 20.35 9.5 1.42E-11 65.15 64.04 0.73 0.55 14.38 
0.65 (0.61, 
0.70) 










MIP-1α 9.28 3.15 1.14E-13 78.03 49.81 0.7 0.61 3.16 
0.67 (0.62, 
0.71) 
MIP-1β 1884.31 210.42 5.82E-13 78.54 49.81 0.7 0.61 211.62 
0.67 (0.62, 
0.71) 
IL-2 25.79 6.7 5.82E-13 72.58 56.18 0.71 0.58 10 
0.67 (0.63, 
0.71) 





30.26 15.06 1.49E-15 68.19 64.8 0.74 0.58 19.13 
0.68 (0.64, 
0.72) 
IL-1β 997.42 310.42 1.49E-15 71.21 61.04 0.73 0.59 587.88 
0.69 (0.64, 
0.73) 
FGF 15 4.63 1.49E-15 61.61 70.41 0.76 0.55 11.18 
0.69 (0.65, 
0.73) 



















TB = Tuberculosis, ORD= other respiratory diseases, Sens= sensitivity, Spec= Specificity, PPV= 
positive predictive value, NPV= negative predictive value, CI = confident interval and AUC= area 































MMP-3 535 442 4.19E-02 81.91 27.86 0.63 0.5 219 
0.55(0.50,0.
59) 
OPN 137.8 137.8 2.19E-02 25.88 84.73 0.72 0.43 175 
0.55(0.51,0.
59) 
LIGHT 11 8 2.19E-02 54.02 58.02 0.66 0.45 10 
0.56(0.51,0.
60) 
sIL-6Rα 133 70 2.17E-03 38.19 76.72 0.71 0.45 256 
0.58(0.53,0.
62) 
IL-8 18200 5299 3.12E-05 78.39 41.99 0.67 0.56 2699 
0.60(0.56,0.
64) 
APRIL 1103 118268 7.24E-08 66.79 60.05 0.52 0.73 3843 
0.63(0.59,0.
68) 
sTNFR1 120 22.48 1.90E-09 56.53 67.94 0.73 0.51 64 
0.64(0.60,0.
68) 
sTNFR2 122 33 4.16E-10 64.07 62.21 0.72 0.53 66 
0.65(0.61,0.
69) 
BAFF 9753 2612 4.07E-15 82.24 50.00 0.70 0.67 2784 
0.68(0.64,0.
72) 








TB = Tuberculosis, ORD= other respiratory diseases, Sens= sensitivity, Spec= Specificity, PPV= 
positive predictive value, NPV= negative predictive value, CI = confident interval and AUC= area 


































EGF 835 466.72 4.63E-02 0.02 1.00 1.00 0.58 283.34 
0.58 (0.52, 
0.64) 
TNF-α 39.87 9.5 5.73E-03 46.39 71.13 0.69 0.49 23.87 
0.60 (0.54, 
0.66) 
MCP-1 490.8 120.8 5.73E-03 57.11 60.20 0.66 0.53 11.64 
0.61 (0.54, 
0.67) 
MIP-1β 80.17 59.91 8.94E-05 41.75 35.92 0.47 0.31 69.78 
0.64 (0.58, 
0.70) 
MIP-1α 74.68 3.2 3.03E-05 53.04 70.42 0.70 0.52 47.54 
0.65 (0.60, 
0.71) 

















TB = Tuberculosis, ORD= other respiratory diseases, Sens= sensitivity, Spec= Specificity, PPV= 
positive predictive value, NPV= negative predictive value, CI = confident interval and AUC= area 
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Figure 3.2 Graphs of individual markers that performed best in classifying ORD from TB with 
an AUC of ≥0.65 .The diagnostic accuracy are shown in the ROC (A-F) while the median 
concentration difference is represented in boxplots (AA-FF). The data were analysed using 
Logistic regression for ROC curves and Mann Whitney U test to compare median 








 Usefulness of combinations of biomarkers in the diagnosis of TB 
After performing univariate analyses, multiple logistic regression analyses were performed to 
determine if better accuracies could be achieved with multiple host markers. This was determined 
for the 3 different kits used in the study (see section 2.4 for details) and a combined analysis. Prior 
to analysis, the data were divided into training – 80% and test - 20% datasets.  
 27-plex biosignature analyses  
We first evaluated the performance of our previously identified biosignature (IL-13, FGF and IFN-γ), 
which gave 96% correct classification of TB amongst respiratory infected individual in a small sample 
size[152] using the same kit (27-plex Bio-Plex Pro™ Human Th1/Th2 Cytokine Panel).  Analysis with 
our current cohort resulted in an AUC of 0.73(95% CI: 0.67,0.79) and sensitivity of 70%( 95% CI 63, 
77) with a low specificity of 69%( 95% CI: 60, 77). The PPV and NPV were 0.75(95% CI: 0.68,0.82) 
and 0.63(95% CI: 0.55, 0.71) respectively on the training dataset. When the signature was applied 
to the test data, there was minimal change in the performance parameters (Table 3.3.1).  
We next did a broad combination analyses looking at TB and ORD regardless of HIV infection among 
adult patients. The best signature identified was a eight-marker combination consisting of FGF, IL-
1β, IL-8, IL-10, IL-12p70, IL-13, MIP-1β and VEGF. This combination was able to discriminate TB 
from ORD with an AUC of 0.78(95% CI: 0.75, 0.84) with a sensitivity of 79%(95% CI: 75, 84) and 
specificity of 67%(95% CI: 60, 73) for the training set. However, when the signature was applied to 
the test dataset, there was a drop in performance with an AUC of 0.67 (95% CI: 0.57, 0.77), with 
sens = 67%(95% CI: 56, 78) and  spec = 67%(95% CI: 54, 80). In addition, no increased performance 
was seen when only HIV negative adults were analysed (data not shown).  
When all age groups were analysed but excluding HIV-positive individuals, a  twelve-marker 
signature was obtained discrimating TB and ORD with an AUC of 0.81(95% CI: 0.77, 0.84), 
sensitivity of 75%(95% CI: 71, 80) and specificty of  76%( 95% CI: 70, 80) for training dataset. 
However, a drop in performance was observed when applied to test dataset with an AUC of 0.71(0.95 
CI: 0.63, 0.8), sensitivity of 55%( 95% CI: 44, 66) but with an increased in specificity of 90%(95% CI: 
82, 97). When the analysis included the HIV-positive individuals, a small drop in sensitivity and an 
increase in specificity were observed (Table 3.2.1). When only individuals <18 were analysed, a four-
marker signature (FGF, IL-4, MIP-1a and RANTES) differentiated TB from ORD, with an AUC of 
0.87(0.95% CI: 0.75, 0.99), sens= 82%(95% CI: 64,100) and specificity of 87%(95% CI: 73, 100).   
Furthermore, when individuals who were smear negative but culture positive were excluded from the 








found (FGF, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-13, MIP-1β, TNF-α  and VEGF) with an AUC of 
0.81 (0.95 C:I 0.77, 0.85), sens= 81(95% CI: 76, 86) and spec= 68(95% CI: 62, 75) on the training 
dataset, while on the test data, an AUC of 0.72  (0.95% CI: 0.63, 0.82), sensitivity of 63(95% CI: 50, 
75) and specificity of 78%(95% CI: 66, 89) was observed.  
Surprisingly, when HIV-positive individuals were excluded from the smear positive culture positive 
and ORD, there was a decrease in peformance AUC=0.77(0.95% CI: 0.72,0.82) sens=78%(95% CI: 
73, 84) but a gain in specificity, thus spec=70%(95% CI: 64, 77) when this signature (IFN-ү, IL-1β, 
IL-8, IL-10, IL-12p70, MIP-1β, RANTES and VEGF) was applied to test data, no change in accuracy 
was observed (Table 3.3.1).  
When smear negative but culture positive TB patients were analysed, a three-marker signature (IL-
1β, IL-7 and VEGF) showed an optimal performance with an AUC=0.74(0.95% CI: 0.60, 0.87) , 
sens= 86%(95% CI: 71, 100) and spec= 60%(95% CI: 45, 75). A final analyses for the 27-Plex 
markers was done on coinfected (TB/HIV+) verse ORDs, two combined markers (VEGF and 
RANTES) showed the potential to classify coinfected patients from ORD with an AUC of 0.78 (95% 
CI: 0.65, 0.91), with low sensitivity of 56%(95% CI: 32, 81) and specificity of 90%(95% CI: 80, 99). 
 
 
Table 3.3.1 Biosignature classification with the 27-plex kits  











FGF, IFN-ү and IL-13 
 








Only adults including HIV infected participants 
FGF, IL-1β, IL-8, IL-10, 
IL-12p70, IL-13, MIP-1β 
and VEGF 








All patients including HIV infected 
Eotaxin, FGF, GM-CSF, 
IFN-ү, IL-1β, IL-6, IL-8, 
















IL-10, IL-12p70, IL-13, 
MIP-1β and TNF-β 




All patients excluding HIV infected 
Eotaxin, FGF, GM-
CSF,IFN-ү, IL1-β, IL-8, 
IL-10, IL-12p70, IL-13, 
PDGF.bb , RANTES and 
VEGF 
 








Smear positive –culture positives including HIV infected 
FGF, IL-1β, IL-6, IL-8, 
IL10, IL-12p70, IL-13, 
MIP-1β, TNF-α  and 
VEGF 








Smear positive – culture positive without HIV infected 
IFN-ү, IL-1β, IL-8, IL-10, 
IL-12p70, MIP-1β, 
RANTES and VEGF 








Smear negative – culture positive only 






HIV infected only 





FGF, IL-4, MIP-1α and 
RANTES 






Sens= sensitivity, Spec= Specificity, PPV= positive predictive value, NPV= negative predictive 











 37-plex biosignature analysis  
Similar analyses were also perfomed for the 37-Plex kit. A thirteen-marker signature was found to 
discrimate TB from ORD with an AUC of 0.83(95% CI: 0.80, 0.86), sensitivity of 71%(95% CI: 66, 
76) and specificity of 81%(95% CI: 76, 86) in the training dataset, regardless of age bracket and HIV 
status of the participants. Conversely, application of this signature to the test data showed dropped 
in performance, AUC of 0.78(95% CI 0.70, 0.85), increased sensitivity (79(95% CI 70, 87) but 
decreased specificity of 70(95% CI 58, 82). When HIV+ individuals were excluded, no significant 
change in marker performance was observed. Furthermore, when only adults data were analysed, 
a fourteen-marker sigature was able to classify TB from ORD with an AUC of 0.84(95% CI: 0.8, 
0.88), sens=83%(95% CI: 78, 87) and spec=76%(95% CI: 70, 82) irrespective of HIV status. A similar 
performancce was seen, when the signature was applied to the test data (Table 3.3.2.). Next, we 
considered only the  smear positive/culture positive TB  with the exclusion of HIV. For this analysis, 
a sixteen-marker biosgnature was found to discriminate TB and ORD with an AUC=0.87(95% CI: 
0.84, 0.91), with a sensitivity of 84%(95% CI: 80, 89) and specificity of 79%(95% CI: 73, 85). When 
the signature was applied to the test data, a drop in performance and sensitivity was observed, AUU 
of 0.78(95% CI 0.68, 0.87), sensitivity of 76(95% CI 64, 88) and slight change in  specificity 80(95% 
CI 68, 91). A combination of two markers (BAFF and sIL6Ra) was able to discriminate culture 
positive-smear negative TB from ORD with an AUC of 0.71(95% CI: 0.58,  0.85), with a sensitivity of 
64%(95% CI: 44, 84) and specificity of 74%(95% CI: 61, 88), while a five-marker signature (BAFF, 
C3.L1, IL-22, MMP-3 and sTNF.R1) was able to discriminate TB/HIV co-infected patients from ORD 
with an AUC of 0.90(95% CI: 0.82, 0.99), sens=88%(95% CI: 71, 100) and spec= 85%(95% CI: 73, 











































all patients’ data including HIV positives  
gp130, IFN-ү, IL-10, IL-22, IL-
27.p28, IL-28A,LIGHT, MMP-11, 






















Adults patients excluding HIV co-infected 
APRIL, BAFF, gp130, IFN.α2, 
IFN-ү, IL-22, IL-28A, LIGHT, 
MMP-1, MMP-2, Osteocalcin, P3, 





















Smear positive – culture positive with no HIV co-infected  
APRIL, BAFF, gp130, IFN-ү, IL-2, 
IL-8, IL-10, IL-22, IL-28A, LIGHT, 
MMP-1, MMP-2, P3, sTNF.R1, 





















Only smear negative – culture positive  











Only HIVTB co-infected  












Sens= sensitivity, Spec= Specificity, PPV= positive predictive value, NPV= negative predictive 











 38-plex biosignature analyses  
For the 38-plex analyses, an eleven-marker biosignature identified TB from ORD with an AUC of 
0.78(0.95 CI: 0.73, 0.84), sensitivity of 78%(95% CI: 73,  85) and specificity of 74%(95% CI: 65, 82) 
regardless of HIV status or age. However, when the signature was applied to test data a declined 
performance was observed, with an AUC of 0.71(95% CI: 0.58, 0.84) significant decrease sensitivity 
of 40(95% CI: 24, 56) and increased specificity of 96(95% CI: 89, 100)  (Table 3.3.3).  When analysis 
was performed on only adult patients including those with HIV infection, a biosignature of 11 markers 
gave an AUC of 0.82(95% CI: 0.77, 0.88), sens=83%(95% CI: 76, 90) and spec=70%(95% CI: 61, 
79). When applied to the test data, its performance ( AUC) and sensitivity dropped to an of 0.67(95% 
CI: 0.52, 0.81) and  59(95% CI:42, 76) respecticvely while specificity increased to 87(95% CI: 76, 
97). 
Likewise, when smear+culture+ TB were compared to ORD with the exclusion of the HIV infected, 
an eight-marker (FGF-2, GM-CSF, IFN.-ү, IL-7, IL-12p40, IP-10, MIP-1α, TNF-α) signature was able 
to identify TB from ORD with an AUC of 0.79(95% CI: 0.73, 0.85), sens=  71%(95% CI: 63, 80) and 
spec=79%(95% CI: 71, 87) as the obtained signature was applied to the test data, an  AUC of 
0.70(95% CI: 0.56,0.85), sensitivity equal to 73(95% CI: 58, 89) and specificity of   63(95% CI: 43, 
82) were attained. No single or combination of marker(s) was able to differentiate culture positive - 
smear negative or TB/HIV+ from ORD.  
In the 27-plex analyses, we observed that the top 7 markers (GM-CSF, FGF, IL-12p70. IL-10, TNF-
α. IL-6, IL-8) were the most likely markers to frequent any potential biosignature from this dataset.  
With FGF, IL-1β and IL-12p70 dominating in the number of appearance among the generated  
signature (Table 3.3.1).  Similarly for the 38-plex analyses, FGF-2, GM-CSF, IFN-ү, MIP-1α and IP-
10 were the most common markers observed (Table 3.3.3). However, in the 37-plex, there was no 
particular order to determine the selection of markers, due to the number of combined markers in 
most signatures. The frequent of marker in  various potential signatures sems to correspond with the 
level of importance of the marker as shown in the variable importance graph (Figure. 3.3). Thus 



































All patients including HIV positive co-infected 
FGF-2, G-CSF, GM-CSF, 
IFN-ү, IL-12-p40, IL-13, IL-




















Adult patients including HIV positive 
FGF-2, G-CSF, GM-CSF, 
IFN-y, IL-6, IL-7, IL-13, IP-


















Smear positive – culture positive TB patients only 
FGF-2, GM-CSF, IFN-y, IL-


















Table 3.3.3. Biosignature classification with the 38-Plex kits 
Sens= sensitivity, Spec= Specificity, PPV= positive predictive value, NPV= negative predictive 























































































































































































































































































































































































































































Figure 3.3 shows overall importance of marker in a possible involvement in a biosignature 
formation.  Graph A= 27-Plex, B=37-Plex and C=38-Plex. The height of the bar indicates level of 












 Combined biosignature analyses  
Finally, when we pooled the 27- and 37-plex data together and did a combined analysis the most 
promising signature was generated when limited to HIV negative, smear+culture+ adult TB 
compared to HIV negative, adult ORD. An eighteen-marker signature (gp130, IL-1β, IL-8, IL-10, IL-
10*, IL-12p70, IL-12p70*, IL-13, IL-22, IL-28A, IFN-ү, IFN-ү*, LIGHT, MMP-1, MMP-2, OPN, 
RANTES, VEGF,) was able to classify TB with 83% accuracy (95% CI:82., 83.7), with an AUC of 
0.89(95% CI:0.86, 0.93), sensitivity of  79(95% CI: 73, 84) and specificity of 88(95% CI: 83, 93) in 
the training dataset. When signature was applied to test data, there was a slight drop in accuracy of 
classification to 76.4 % (95% CI: 76.1, 76.7), AUC to 0.82(95% CI: 0.74, 0.89), sensitivity to 
74(95%CI: 64, 84) and specificity to 80(95% CI: 70, 91).  There were some markers which were 
duplicated because they were present in both kits such as IL-10, 12p70 and IFN-ү which are noted 
by an asterisk (*). The next promising biosignature was a two-marker signature (IL.29, IFN.λ1, PTX3) 
which discriminated the smear-culture+ from ORD with AUC of 0.68(95% CI: 0.52, 0.85), sensitivity 
of 67(95% CI: 48, 86) and specificity of 95(95% CI: 88, 100) with 83.9% (95% CI: 83.4, 84.3) 
accuracy.  The 38-plex kit was excluded from the combined analyses because we did not found 
discrimination with it, and most of the markers were also found to strong correlate with markers from 
























 Treatment response and monitoring  
A subset of patients with confirmed TB were followed up for the duration of treatment, with sputum 
collected Month 1 and Month 2 for microbiological and host marker evaluation.  34 (7.94%) patients 
provided enough sputa at month 1 only and 39 (9.11%) at month 2 only, with 21(4.91%) patients at 
both time-points.  At the end of the 2 months intensive TB treatment phase, 15 (3.51%) patients 
remained culture or smear positive while the rest were microbiologically negative. In this analyses, 
only markers from the 38-Plex kit were evaluted. We performed a Wilcoxon Ranked sum test to  
assess changes in the analyte levels during the course of treatment for those individuals who 
provided samples at baseline and month 1 or 2. Friedman test was used to compare diffrences in 
the mean levels of makers for patients who had samples available at both follow-up time-points, 












Smear positive – culture positive combine data 
gp130, IL-1β, IL-8, IL-
10, IL-12p70, IL-13,  IL-
10*, IL-12p70*, IL-22, 
IL-28A, IFN-ү, IFN-ү*, 
LIGHT, MMP-1, MMP-


























 Smear negative – culture positive TB patients only 












Sens= sensitivity, Spec= Specificity, PPV= positive predictive value, NPV= negative predictive 













 Host markers’ levels during the course tuberculosis treatment  
When the median levels of the sputum markers at 1 or 2 months were compared to the baseline, 15 
markers (EGF, Eotaxin, TGF-α, G-CSF, GM-CSF, GRO, IL-1 α, IL-1β, IL-8, IL-3, MCP-1, TNF-α, IP-
10, MIP-1β and MIP-1α (Fig 3.4.1A)  showed a significant decline in their median levels by the first 
month of treatment. 13 markers (EGF, Eotaxin, TGF-α, GM-CSF, IL-1α, IL-1β, IL-8, MDC, MIP-1α, 
MIP-1β, TNF-β, and MCP-1 ) were also significantly lower when Month 2 was compared to baseline. 
When patients with all 3 time points available were analysed, IL-1β, IL-1α, IL-8, Eotaxin, EGF, 
Fractalkine, MIP-1α, MIP-1β and TNF-α all showed changes with treatment (Fig 3.4.1C).  IL-1α and 
IL-1β were significantly lower at Month 1 and 2 compared to baseline (p=0.00062 and p=0.01514 
respectively; Figure 3.4.1C). However, there was no significant change between Months 1 and 2. IL-
8, EGF, TNF-α and MIP-1α showed a slight but significant decline by Month 1 compared to baseline 
(p=0.036, p=0.015, p=0.0058 and p=0.044 respectively), but remained unchanged at 2 months 
(Figure 3.4.1C). Eotaxin, Fractalkine and MIP-1β were found to be significant when the three time 
points were compared, however, no significant difference were observed between their individual 
pairs (Figure 34.1C).   
We also performed a Mann-Whitney U-test to compare the median levels of fast (i.e. smear negative 
by 2 months) and slow (i.e. smear positive at 2 months but negative by 6 months) treatment 
responders.  EGF, FGF-2, TGF-a, GMCSF, Fractalkine, IFN-ү, IL-10, MCP-3, IL-12p40, IL-12p70,IL-
15, sCD40L, IL-2, IL-7, MCP-1, TNF-α and TNF-β all showed higher levels in slow responders 

























































































































































































































































Figure 3.4.1A.  The levels of markers been compared from corresponding samples of the same patient 













































































































































































































Figure 3.4.1B Markers showed decline in concentration levels when baseline and 2months 
































Figure 3. 4.1C Changes in mean levels of markers during the course of treatment.  
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 Biosignature of treatment responses 
Following single biomarker analysis, we performed multiple logistic regression analysis to identify a 
potential biosignature that could predict fast and slow treatment responders. The fast responders 
are participants who had culture and smear converted to negative in the first 2 months of treatment, 
while slow responders remained culture or smear positive after 2 months of treatment. A four-marker 
signature (EGF, IL-15, MIP-1β and TNF-β) was able to discriminate fast from slow responders with 
with an AUC of 0.74(95% CI: 0.57, 0.91), sens= 75%(95% CI: 54, 96) and spec=  80% (95% CI: 75, 
86)  


























Fast verse slow responders  
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0.97(0.95, 
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Sens= sensitivity, Spec= Specificity, PPV= positive predictive value, NPV= negative predictive 































 Discussion  
 
 Main findings 
The availability of a more efficient TB diagnostic test could revolutionise patient management, thus 
impacting on the transmission chain of the disease. This is particularly important since 10 million 
people are estimated to have TB disease every year, with a single patient prior to treatment having 
the potential to infect close to 15 people per annum [19]. In addition, about 70% of TB cases resided 
in poor resource settings [1] where they may not have access to, or be able to afford the cost of 
current TB tests. The worst  of all, majority of these people visit primary health care facilities where 
there is no laboratory tests for TB, relying on clinical diagnosis despite the known limitations of clinical 
diagnosis, more so the overlapping symptoms of respiratory diseases [4]. Thus, the aim of this 
project was to determine optimal single host markers or biosignatures in ex vivo sputum samples 
that could diagnose pulmonary tuberculosis among individuals who present with symptoms of 
respiratory disease prior to microbiological confirmation. The specific objectives were a) to validate 
our previously identified biosignature in a larger sample size and to determine new signatures using 
an extensive panel of analytes; b) to assess the accuracy of the markers or biosignature in relation 
to different microbiological test outcomes; c) to investigate signatures that could be useful in HIV co-
infected individuals or childhood and finally, to identify signatures that could predict treatment 
response.  
In this study, we found most markers’ median levels to be significantly higher in TB than ORD, with 
the most differential markers having a diagnostic performance (AUC) ≥ 0.60. The best single 
classifiers of TB disease from other respiratory disease were: IL-1β, FGF, GMCSF, RANTES, BAFF 
and MMP-2 with an AUC ≥0.68 (Table 3.2A-C). In general, MMP-2 was the most outstanding single 
classifier in the study with an AUC of 0.73, which is still too low for a diagnostic or screening test. 
Though, some of the markers did not do well as single classifiers of TB, their frequent appearance 
in the generated signatures suggested their importance as potential markers of TB disease. The 
setback, however is, some of the markers such as FGF, GM-CSF and IL-12p70 which appeared in 
almost every generated signature has a low concentration in sputum. High concentration of the 
markers would be preferred. It would be easier to detect highly concentrated markers when adapted 
into lateral flow test or any portable diagnostic device. For instance, it is easier to detect the MMP-2 
with a cut-off of 9273pg/ml than FGF with concentration cut-off 11pg/ml in sputum. With new 
technologies increasing the sensitivity of antibodies on lateral flow devices, this limitation may not 








Among the three kits analysed, the 38-plex single markers did not show good diagnostic potential in 
this study, with MIP-1α and IL-1β showing a sub optimal performance with AUCs of 0.65 and 0.66 
respectively as highest performers (Table 3.2C). The poor performance could be attributed to sample 
type used but this is unlikely given that the other kits used were also developed for use in serum and 
plasma but not sputum. Another factor could be the duration of incubation after sample addition. The 
manufacturer recommended either a two-hour (2hr) or an overnight incubation and we opted for the 
2hr incubation, which may also contribute to poor performance of the markers. However, the 
manufacturer must have optimised the assays for the 2hr incubation period and hence the 2hr 
incubation period may not completely explain our observations. Nonetheless the predictive ability of 
the markers were enhanced by the addition of other markers into a biosignature.  
Furthermore, in this study, the data was stratified based on the microbiological test outcome (i.e. 
smear negative versus smear positive), HIV status and age. And the optimal signature found was 
an eight-marker signature (IFN-ү, IL-1β, IL-8, IL-10, IL-12p70, MIP-1β, RANTES and VEGF) with a 
sensitivity of 78% and specificity of 69% on the test data. This signature showed the potential to 
diagnose adult HIV negative smear positive/culture positive TB amongst total respiratory diseases 
but  the limitation is it does not meet the WHO target product profile (TPP) criteria [sensitivity 90% 
and specificity 70%] for diagnosing pulmonary TB. So new studies are required to redefine the 
signature and some of the promising markers of in the study. We also had the previously discovered 
signature (IL-13, IFN-ү and FGF) in the pilot study validated in this study, however, its performance 
(sensitivity 70% and specificity 62%) on the test data does not meet the WHO criteria for either a TB 
diagnostic or triage test. Other signatures were also identified for the difficult to diagnosed form of 
TB (smear negative/culture positive, TB/HIV co-infected and children). In the children dataset, we 
had induced sputum from the under 5 years, though the numbers were small (4) but with high levels 
of cytokines, thus unlikely to have affected the results. Knowing the diagnostic difficulties associated 
with childhood, smear negative or TB/HIV+ patients due to paucibacillary disease, these signatures 
show promise in resolving this. The limitation with some of the identified signatures were the number 
of markers included were large, translating them into a single point care device would be difficult. 
New studies are needed to redefine the best markers in diagnosing TB as well as their applicability 
in a POC test.  
In addition to understanding the diagnostic performance of these markers, we also investigated the 
usefulness of the markers in treatment monitoring amongst the TB cases. In these analyses, we only 
assessed the 38-plex data, at baseline, 1month and 2month. Due to limited resources the other kits 
were not tested. EGF, Eotaxin, Fractalkine, TGF-α, G-CSF, GM-CSF, GRO, IL-1α, IL-1β, IL-8, IL-3, 








TB treatment response. Furthermore, we have discovered a 4-marker biosignature consisting of 
EGF, IL-15, MIP-1β and TNF-β that could differentiate TB patients into slow or fast treatment 
responders at baseline in relation to smear or culture outcome at 2-months with a sensitivity of 75% 
and specificity of 80%. We also found median levels of markers in the biosignature to be elevated 
among slow responders compare to the fast responders, suggesting a difference in the 
immunological activities during TB disease between the two groups. The difference may be attributed 
to severity of disease, leading to prolonged inflammation, thus reflecting in the response to treatment.  
Again, an ideal new TB test should be rapid (generate result within 20minutes), accurate, 
inexpensive and the test sample easily accessible. With the availability of lateral flow technology, 
the translation of immunodiagnostic markers into the lateral flow assays (LFA) would be beneficial. 
Lateral flow assays are known to be easy to use and provide results within a short time [114]. The 
employment of the technology will drastically reduce lost to follow-up occurring due long duration 
before results are known. More so it will impact on the number of diagnosed individuals as well 
prevent unnecessary treatment of non TB patients. This in itself reduces the cost associated TB 
patient management. Moreover, the utilisation of a laboratory free diagnostic test like sputum 
immunodiagnostic marker as a point of care test in the peripheral healthcare centres could mitigate 
the challenge of missing potential TB cases as well as fasten the time to treatment initiation. Thus, 
availability of the test would allow speedy testings alongside treatment acceleration or less/more 
referral to confirmatory testing with the standard TB tests. In addition, the test would provide 
information on infection/disease spectrum, identifying patients who might urgently require treatment.  
Of recent, exploration of ex vivo host markers have been shown to be useful and promising in 
diagnosing TB disease.  Easily obtainable samples such as serum, plasma, saliva or urine are been 
investigated for a potential biomarker or signature of TB infection or disease [125], [145].  Various 
studies have shown promising findings in ex vivo TB biomarkers or signatures in serum, plasma and 
saliva [126], [129], [154]. Some of the studies observed a higher concentration of MIP-1𝛽, MCP-1, 
sCD40L, MIP-1𝛽, fractalkine, IFN-ү, IP-10, TNF-α, VEGF, IL-6, IL-9, IL-5, IL-17 and IL-33 among TB 
participant compared to ORD [154]. A similar pattern was also observed in this study, with most of 
the markers been higher in TB compared to ORD. In a saliva study, which was published by Jacob 
et al in 2016, the investigators reported a promising six-marker signature regardless of HIV status 
with a sensitivity of 100% and specificity of 89% [125] though the sample size were small. A similar 
study was by the same group using ex vivo saliva and serum discovered a five-marker signature 
from the saliva dataset differentiated TB from ORD with a sensitivity of 78% and specificity of 83% 
[145]. Urine was also assessed but the obtained urine marker (LAM) was found to be most useful 








ex vivo host marker for TB disease can be attained. More so various high performed signatures were 
also reported by different investigators using ex vivo samples [129], [154]. Of recent a seven-marker 
signature obtained from serum with a sensitivity of 78% and specificity of 83% was validated in a 
finger prick blood test (manuscript in preparation), three markers (CRP, SAA and IP-10)  from this 
signature showed promising results [129]. The intension is to further validate the three markers as a 
triage TB test in a laboratory free environment for screening of TB. These findings further stresses 
the important use of ex vivo samples in finding a potential immunodiagnostic marker for TB.  Although 
a lot of biomarkers of TB infection or disease were discovered, most have not gone to the validation 
stage. The setback with most of these studies were; they either use small sample size, stimulated 
samples and/or samples (serum, plasma or pleural fluid) not obtained from the site of infection.  
Similarly, in our pilot study with the use of ex vivo sputum we found promising sputum biomarkers in 
high levels [152]. Thus this study was done to validate the performance of the previous discovered 
signature in the pilot study and to find potential new signatures in a large cohort. The use sputum is 
advantageous for many reasons; it is a routine sample for diagnosing TB, obtaining the sample is 
non-invasive and sample collection requires no trained personnel, but the patient’s ability to produce 
the sputum. Moreover, the sputum sample is already been collected and used in resource limited 
settings, so the use of sputum signature for diagnosis of TB as a point of test would not be a 
challenge in these settings. More so it would help mitigate the limitation of the current diagnostic 
tests. In addition, an obtained sputum biomarker or signature would allow direct comparison with the 
current routine sputum diagnostic tests for TB thus limiting the challenge of sample variability.  Again, 
been able to predict the treatment outcome, the sputum biomarkers or signature would provide 
information like disease severity in relation to smear grade or GeneXpert cycle threshold values or 
the chest x-ray score for personalised treatment. So a sputum marker or signature is vital in various 
aspect for the patient and healthcare provider in terms of time to results, treatment decision and 
general patient management. Above all, the available of sputum point of care test will quickly identify 
the most infectious patients, accelerate treatment and obviously reduce transmission. Additionally, 
the sputum signature would provide information for the difficult to diagnosed form of pulmonary TB.  
Similarly, the importance of developing an immunological marker test for treatment response cannot 
be overemphasised. Sputum culture conversion at 2 months is currently the only acceptable marker 
of treatment monitoring, and its predictive ability is lower than 40% [30]. In addition, it is based on 
detecting the presence of pathogen or its product, therefore its turnaround time is a limitation. It is 
also very difficult to obtain quality sputum during the course of treatment, therefore, the availability 
of markers at baseline that can predict the outcome of treatment would help to mitigate this problem. 












 Strengths and weaknesses  
The study’s main strength was the large sample size that allowed us to split the data into training 
and test datasets. It also gave us the opportunity to test our previously defined biosignature on a 
new dataset and to investigate accuracy in smear positive/culture positive, smear negative/culture 
positive, children and HIV co-infected subjects although more samples are required for validation in 
children and HIV-positive due to low numbers. Other advantages included the multiple 
microbiological tests performed on single patient samples and the number of analytes used. 
However, despite the large sample size, the challenges of this study were not being able to confirm 
the final disease classification of the ORD group (i.e. infection or chronic pathology) and obtaining 
sputum from TB patients during course of treatment beyond 2 months. Not collecting sputum beyond 
2 months obviously affect treatment response evaluation. Moreover our samples were highly 
heterogynous with some samples having only smear microscopy performed as an approved 
diagnostic test, with MBLA as a confirmatory test.  The disadvantage with MBLA was, it is not an 
approved TB diagnostic test even though it was sensitive in picking out TB.  Finally, since Gambia 
has low HIV prevalence, more studies are needed to assess the effect of HIV co-infection together 
with CD4 counts on these markers.  
 Implications of the study 
The result shown in this thesis is not conclusive, although it shows interesting finding which can be 
further investigated in various settings. In this study, we have seen promising results with ex vivo 
sputum markers as potential diagnostics markers of TB disease. With a combination of markers 
discriminating TB from ORD and also predicting the outcome of treatment. Since sputum is a readily 
available sample, easily collected and routinely used for TB diagnosis, obtaining a sputum based 
point of care test would be useful in resource poor settings with high burden of TB. Therefore, the 
role of these immunological markers in predicting TB or outcome of treatment should be further 
investigated. With this in mind, the markers discovered in thesis would enhance that understanding 
in future studies. The study also provide information about the performance of the markers based 
on the microbiological outcome, HIV status and age with data from smear positive/culture positive 
TB showing best performed markers or signatures. Again, these results need further investigation. 








treatment.  The growing interest in ex vivo samples analyses with intension of translating the finding 
into a point-of-care test which could be used in any part of the world most especially in remote setting 




There is an urgent need for an accurate, rapid and inexpensive diagnostic test to curb TB, one of 
the single most deadly diseases to plague mankind. We have discovered novel sputum host 
biomarkers and biosignatures for screening of tuberculosis and predicting outcome of treatment.  
Since sputum is easily available, performing sputum point of care test would not be a problem in 
rural settings with no infrastructure. The availability of such a triage test will provide several 
opportunities in fight against the TB pandemic. It will mitigate most of the limitations associate with 
current diagnostic tests (Xpert and culture), such as cost, infrastructure, turnaround time for results 
and requirement for skilled personnel. With an affordable and fast triage test and an improved 
sensitivity, most of the possible TB would detected. At the moment, a similar triage test using 
fingerprick blood is under evaluation in our laboratory in collaboration with SUN. This test has been 
developed as a multi-plex lateral flow test in Leiden based on a finger prick blood using three markers 
(IP-10, SAA1 and CRP). Development of a test that is sensitive and specific for diagnosis is not 
enough but the cost and rolling out of the test to lower tiers of health system is key for its usefulness.  
Therefore, the availability of a TB triage test that could be used in remote health posts, homes or 
communities with less training like in the blood sugar, pregnancy or rapid Malaria tests would have 
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